AXA/2025/FY/Earnings presentation: Difference between revisions
Appearance
< AXA
Content deleted Content added
PlumBot: publish from draft |
PlumBot: publish from draft |
||
| Line 19: | Line 19: | ||
=== Full Year 2025 earnings presentation === |
=== Full Year 2025 earnings presentation === |
||
* |
* '''Presentation date''' February 26, 2026 <sup>p. 1</sup> |
||
* '''Company''' AXA <sup>p. 1</sup> |
|||
=== Important legal information and cautionary statements concerning forward-looking statements and the use of non-GAAP financial measures === |
=== Important legal information and cautionary statements concerning forward-looking statements and the use of non-GAAP financial measures === |
||
* '''Forward-looking statements''' |
* '''Forward-looking statements''' include predictions of future events, trends, plans, expectations, or objectives <sup>p. 2</sup>. |
||
* |
* '''Underlying EPS''' (UEPS) growth guidance for 2026 is provided as one-off guidance in the context of the last year of the Group's current strategic plan <sup>p. 2</sup>. |
||
* ''' |
* '''Risk factors''' are described in Part 5 of AXA's Universal Registration Document for the year ended December 31, 2024 <sup>p. 2</sup>. |
||
* '''Alternative performance measures''' (APMs) used by management include underlying earnings, UEPS, underlying return on equity, combined ratio, and debt gearing <sup>p. 2</sup>. |
|||
* AXA's consolidated financial statements for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of an audit procedure <sup>p. 2</sup>. |
|||
* '''Financial statements''' for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of audit procedures <sup>p. 2</sup>. |
|||
=== Table of contents === |
=== Table of contents === |
||
* '''FY25 Highlights''' presented by Thomas Buberl, Group CEO <sup>p. 3 |
* '''FY25 Highlights''' presented by Thomas Buberl, Group CEO <sup>p. 3</sup> |
||
* '''FY25 Business Performance''' presented by Guillaume Borie, Global Head of Finance, Strategy, Underwriting, Risk, and Technology <sup>p. 3 |
* '''FY25 Business Performance''' presented by Guillaume Borie, Global Head of Finance, Strategy, Underwriting, Risk, and Technology <sup>p. 3</sup> |
||
* '''FY25 Financial Performance''' presented by Alban de Mailly Nesle, Group CFO <sup>p. 3 |
* '''FY25 Financial Performance''' presented by Alban de Mailly Nesle, Group CFO <sup>p. 3</sup> |
||
== FY25 Highlights == |
== FY25 Highlights == |
||
* |
* '''Session presenter''' Thomas Buberl, Group CEO <sup>p. 4</sup> |
||
=== Full Year 2025 | Excellent performance === |
=== Full Year 2025 | Excellent performance === |
||
<div style="overflow-x:auto"> |
|||
* '''Revenues''' +6% vs. FY24 <sup>p. 5</sup>. |
|||
{| class="wikitable" |
|||
* '''Underlying EPS''' +8% vs. FY24 <sup>p. 5</sup>. |
|||
|+ Key financial highlights, FY25 <sup>p. 5</sup> |
|||
! style="text-align:left" | Metric |
|||
* '''Solvency II ratio''' 224% for FY25 <sup>p. 5</sup>. |
|||
! class="col-m" style="text-align:right" | Value |
|||
* '''Shareholder value delivery''' supported by +8% DPS growth and EUR 1.25bn annual share buyback <sup>p. 5</sup>. |
|||
|- |
|||
** Dividend proposed by AXA's Board of Directors on February 25, 2026, subject to approval by the Shareholders' Annual General Meeting on April 30, 2026 <sup>p. 5</sup>. |
|||
| style="text-align:left" | Revenues |
|||
** Share buyback approved by the Board of Directors on February 25, 2026, expected to commence as soon as reasonably practicable <sup>p. 5</sup>. |
|||
| class="col-m" style="text-align:right" | +6% vs. FY24 |
|||
* '''Management outlook''' expresses confidence to deliver underlying EPS growth at the upper end of the 6% to 8% target range for 2026 <sup>p. 5</sup>. |
|||
|- |
|||
| style="text-align:left" | Underlying EPS |
|||
| class="col-m" style="text-align:right" | +8% vs. FY24 |
|||
|- |
|||
| style="text-align:left" | Return on equity (ROE) |
|||
| class="col-m" style="text-align:right" | 16% |
|||
|- |
|||
| style="text-align:left" | Solvency II ratio |
|||
| class="col-m" style="text-align:right" | 224% |
|||
|- |
|||
| style="text-align:left" | Shareholder value |
|||
| class="col-m" style="text-align:right" | +8% DPS growth and EUR 1.25bn annual share buyback |
|||
|- |
|||
| style="text-align:left" | Earnings guidance |
|||
| class="col-m" style="text-align:right" | Confident to deliver underlying EPS growth at the upper end of 6%-8% target range for 2026 |
|||
|} |
|||
</div> |
|||
* Dividend proposed by AXA's Board of Directors on February 25, 2026, subject to approval by the Shareholders' Annual General Meeting on April 30, 2026. |
|||
* Share buyback approved by AXA's Board of Directors on February 25, 2026, expected to commence as soon as reasonably practicable. |
|||
=== Executing the plan on growth, margin and efficiency === |
=== Executing the plan on growth, margin and efficiency === |
||
| Line 53: | Line 74: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Underlying earnings, FY24 vs FY25 <sup>p. 6</sup> |
|+ Underlying earnings (constant FX), FY24 vs FY25 <sup>p. 6</sup> |
||
! style="text-align:left" | EUR billion unless otherwise mentioned |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change (LFL) |
||
! class="col-s" style="text-align:right" | Change (excluding AXA IM) |
|||
|- |
|- |
||
| style="text-align:left" | Underlying earnings |
| style="text-align:left" | Underlying earnings |
||
| Line 63: | Line 85: | ||
| style="text-align:right" | 8.4 |
| style="text-align:right" | 8.4 |
||
| style="text-align:right" | +6% |
| style="text-align:right" | +6% |
||
| style="text-align:right" | +9% |
|||
|} |
|} |
||
</div> |
</div> |
||
* Top line growth +6% LFL, well balanced across lines |
* Top line growth +6% LFL, well balanced across lines: P&C +5%, Life +9%, Health +5%. |
||
* Record profitability driven by further margin expansion in P&C and L&H, alongside improvement in efficiency |
* Record profitability driven by further margin expansion in P&C and L&H, alongside improvement in efficiency. |
||
* Scaling the business through continued investments in growth and technology |
* Scaling the business through continued investments in growth and technology. |
||
* |
* Earnings growth delivered consistently while enhancing reserve prudence. |
||
* Footnote: Change for Gross written premiums at constant scope and FX and for underlying earnings at constant FX |
|||
=== Diversified franchise, well positioned in an attractive industry === |
=== Diversified franchise, well positioned in an attractive industry === |
||
| Line 75: | Line 97: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Business mix |
|+ Business mix (FY25 gross written premium split excluding AXA IM and holdings) <sup>p. 7</sup> |
||
! style="text-align:left" | Segment |
! style="text-align:left" | Segment |
||
! class="col-s" style="text-align:right" | Share |
! class="col-s" style="text-align:right" | Share |
||
| Line 97: | Line 119: | ||
* '''Secular trends''' fueling demand across businesses: |
* '''Secular trends''' fueling demand across businesses: |
||
** Protection gaps and emerging corporate risks driving |
** Protection gaps and emerging corporate risks driving SME & Mid-market and Large & Specialty <sup>p. 7</sup> |
||
** Demographics driving demand for private retirement and healthcare driving Life and Health |
** Demographics driving demand for private retirement and healthcare driving Life and Health <sup>p. 7</sup> |
||
* '''Our right to win''' supported by four strategic pillars: |
* '''Our right to win''' supported by four strategic pillars: |
||
** Leading brand & high customer NPS <sup>p. 7</sup> |
** Leading brand & high customer NPS <sup>p. 7</sup> |
||
** Strong and diversified distribution <sup>p. 7</sup> |
** Strong and diversified distribution <sup>p. 7</sup> |
||
** Technical expertise to price & |
** Technical expertise to price & underwriting risks <sup>p. 7</sup> |
||
** Scale offering cost advantage <sup>p. 7</sup> |
** Scale offering cost advantage <sup>p. 7</sup> |
||
=== Laying the foundation for the next plan === |
=== Laying the foundation for the next plan === |
||
* ''' |
* '''Strategic pillars''' for the next plan: |
||
* |
** Clear tech and AI roadmap <sup>p. 8</sup> |
||
* |
** Driving efficiency <sup>p. 8</sup> |
||
* |
** Enhancing capital allocation discipline <sup>p. 8</sup> |
||
* |
** Building resilience <sup>p. 8</sup> |
||
* '''Earnings growth''' sustainability supported by strong confidence <sup>p. 8</sup> |
|||
=== Section divider === |
|||
== FY25 Business Performance == |
|||
* |
* '''FY25 Business Performance''' presented by Guillaume Borie, Global Head of Finance, Strategy, Underwriting, Risk, and Technology <sup>p. 9</sup> |
||
== FY25 Business Performance == |
|||
=== Strong delivery across our businesses === |
=== Strong delivery across our businesses === |
||
| Line 121: | Line 146: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Gross written premiums and underlying earnings by region <sup>p. 10</sup> |
|||
! style="text-align:left" | EUR billion unless otherwise mentioned |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | % of total GWP |
! class="col-s" style="text-align:right" | % of total GWP |
||
! class="col-s" style="text-align:right" | GWP LFL change |
|||
! class="col-s" style="text-align:right" | GWP |
! class="col-s" style="text-align:right" | GWP |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | GWP change LFL |
||
! class="col-s" style="text-align:right" | Underlying earnings |
! class="col-s" style="text-align:right" | Underlying earnings |
||
! class="col-s" style="text-align:right" | Underlying earnings change LFL |
|||
|- |
|- |
||
| style="text-align:left" | France |
| style="text-align:left" | France |
||
| style="text-align:right" | 27% |
| style="text-align:right" | 27% |
||
| style="text-align:right" | 31 |
|||
| style="text-align:right" | +6% |
| style="text-align:right" | +6% |
||
| style="text-align:right" | |
| style="text-align:right" | 2.2 |
||
| style="text-align:right" | +7% |
| style="text-align:right" | +7% |
||
| style="text-align:right" | 2.2 |
|||
|- |
|- |
||
| style="text-align:left" | Europe |
| style="text-align:left" | Europe |
||
| style="text-align:right" | 38% |
| style="text-align:right" | 38% |
||
| style="text-align:right" | +6% |
|||
| style="text-align:right" | 43 |
| style="text-align:right" | 43 |
||
| style="text-align:right" | + |
| style="text-align:right" | +6% |
||
| style="text-align:right" | 3.5 |
| style="text-align:right" | 3.5 |
||
| style="text-align:right" | +9% |
|||
|- |
|- |
||
| style="text-align:left" | AXA XL |
| style="text-align:left" | AXA XL |
||
| style="text-align:right" | 17% |
| style="text-align:right" | 17% |
||
| style="text-align:right" | +4% |
|||
| style="text-align:right" | 19 |
| style="text-align:right" | 19 |
||
| style="text-align:right" | + |
| style="text-align:right" | +4% |
||
| style="text-align:right" | 1.9 |
| style="text-align:right" | 1.9 |
||
| style="text-align:right" | +9% |
|||
|- |
|- |
||
| style="text-align:left" | Asia, Africa & EME-LATAM |
| style="text-align:left" | Asia, Africa & EME-LATAM |
||
| style="text-align:right" | 18% |
| style="text-align:right" | 18% |
||
| style="text-align:right" | +13% |
|||
| style="text-align:right" | 20 |
| style="text-align:right" | 20 |
||
| style="text-align:right" | + |
| style="text-align:right" | +13% |
||
| style="text-align:right" | 1.5 |
| style="text-align:right" | 1.5 |
||
| style="text-align:right" | +6% |
|||
|} |
|} |
||
</div> |
</div> |
||
* Footnotes: Change for Gross written premiums at constant scope and FX and for underlying earnings at constant FX; FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers <sup>p. 10</sup>. |
|||
=== P&C | Strong margins, confidence in sustaining growth === |
=== P&C | Strong margins, confidence in sustaining growth === |
||
<div style="overflow-x:auto"> |
|||
* (pie) '''GWP mix''': EUR 58bn GWP total, split by Retail, SME & Mid-market, and AXA XL (Large & Specialty) <sup>p. 11</sup> |
|||
{| class="wikitable fintable" |
|||
** '''AXA XL''' segment includes AXA XL Re premiums of EUR 2.6bn <sup>p. 11</sup> |
|||
|+ GWP mix <sup>p. 11</sup> |
|||
! style="text-align:left" | EUR billion |
|||
* '''Retail and SME''' strategy: |
|||
! class="col-s" style="text-align:right" | GWP |
|||
|- |
|||
| style="text-align:left" | Retail |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | SME & Mid-market |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | AXA XL (Large & Specialty) |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left; font-weight:bold" | Total |
|||
| style="text-align:right; font-weight:bold" | 58 |
|||
|} |
|||
</div> |
|||
* AXA XL includes AXA XL Re premiums of EUR 2.6bn <sup>p. 11</sup> |
|||
* '''Underlying earnings''' +9% LFL to EUR 5.9bn (reported change FY25 vs. FY24 at constant FX) <sup>p. 11</sup> |
|||
* '''Retail and SME & Mid-market''' strategic outlook: |
|||
** '''2025''': Growing volumes while expanding margins <sup>p. 11</sup> |
** '''2025''': Growing volumes while expanding margins <sup>p. 11</sup> |
||
** '''Beyond 2025''': Investing to improve customer retention & expanding distribution footprint <sup>p. 11</sup> |
** '''Beyond 2025''': Investing to improve customer retention & expanding distribution footprint <sup>p. 11</sup> |
||
* '''AXA XL |
* '''AXA XL (Large & Specialty)''' strategic outlook: |
||
** '''2025''': Profitable growth with stable margins <sup>p. 11</sup> |
** '''2025''': Profitable growth with stable margins <sup>p. 11</sup> |
||
** '''Beyond 2025''': Capitalizing on attractive growth opportunities and continued cycle management <sup>p. 11</sup> |
** '''Beyond 2025''': Capitalizing on attractive growth opportunities and continued cycle management <sup>p. 11</sup> |
||
| Line 181: | Line 222: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ GWP mix by |
|+ GWP mix by Long-term and Short-term <sup>p. 12</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | GWP |
||
|- |
|||
| style="text-align:left; font-weight:bold" | Total |
|||
| style="text-align:right; font-weight:bold" | 57 |
|||
|- |
|- |
||
| style="text-align:left" | Long-term |
| style="text-align:left" | Long-term |
||
| style="text-align:right" | |
| style="text-align:right" | — |
||
|- |
|- |
||
| style="text-align:left" | Short-term |
| style="text-align:left" | Short-term |
||
| style="text-align:right" | |
| style="text-align:right" | — |
||
|} |
|} |
||
</div> |
</div> |
||
* '''Underlying earnings''' +7% LFL to EUR 3.5bn (reported change FY25 vs. FY24 at constant FX) <sup>p. 12</sup> |
|||
* '''Long-term business''' strategic outlook: |
|||
* Underlying earnings +7% at constant FX to EUR 3.5bn <sup>p. 12</sup> |
|||
* '''Long-term business''' strategy: |
|||
** '''2025''': Accelerating net flows in Savings at attractive margins <sup>p. 12</sup> |
** '''2025''': Accelerating net flows in Savings at attractive margins <sup>p. 12</sup> |
||
** '''Beyond 2025''': Capturing savings & retirement opportunity, sourcing best asset management products for our customers <sup>p. 12</sup> |
** '''Beyond 2025''': Capturing savings & retirement opportunity, sourcing best asset management products for our customers <sup>p. 12</sup> |
||
* '''Short-term business''' |
* '''Short-term business''' strategic outlook: |
||
** '''2025''': Growing technical results while absorbing Mexico VAT impact <sup>p. 12</sup> |
** '''2025''': Growing technical results while absorbing Mexico VAT impact <sup>p. 12</sup> |
||
** '''Beyond 2025''': Capitalizing on demand for health & protection while further improving our margins <sup>p. 12</sup> |
** '''Beyond 2025''': Capitalizing on demand for health & protection while further improving our margins <sup>p. 12</sup> |
||
| Line 205: | Line 248: | ||
** Leveraging AI to reduce claims leakage & improve customer outcomes in Health <sup>p. 12</sup> |
** Leveraging AI to reduce claims leakage & improve customer outcomes in Health <sup>p. 12</sup> |
||
== FY25 Financial Performance == |
=== FY25 Financial Performance === |
||
* Section divider slide presented by Alban de Mailly Nesle, Group CFO <sup>p. 13</sup> |
* Section divider slide presented by Alban de Mailly Nesle, Group CFO <sup>p. 13</sup> |
||
| Line 213: | Line 256: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ GWP & |
|+ GWP & Other Revenues by line, FY24 vs FY25 <sup>p. 14</sup> |
||
! style="text-align:left" | EUR billion unless otherwise mentioned |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | LFL Change |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | o/w pricing |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | o/w volume |
||
|- |
|- |
||
| style="text-align:left" | Commercial lines |
| style="text-align:left" | Commercial lines |
||
| style="text-align:right" | |
| style="text-align:right" | — |
||
| style="text-align:right" | 35.8 |
| style="text-align:right" | 35.8 |
||
| style="text-align:right" | +4% |
| style="text-align:right" | +4% |
||
| Line 229: | Line 272: | ||
|- |
|- |
||
| style="text-align:left" | AXA XL Reinsurance |
| style="text-align:left" | AXA XL Reinsurance |
||
| style="text-align:right" | |
| style="text-align:right" | — |
||
| style="text-align:right" | 2.6 |
| style="text-align:right" | 2.6 |
||
| style="text-align:right" | +8% |
| style="text-align:right" | +8% |
||
| Line 236: | Line 279: | ||
|- |
|- |
||
| style="text-align:left" | Retail lines |
| style="text-align:left" | Retail lines |
||
| style="text-align:right" | |
| style="text-align:right" | — |
||
| style="text-align:right" | 19.7 |
| style="text-align:right" | 19.7 |
||
| style="text-align:right" | +7% |
| style="text-align:right" | +7% |
||
| Line 250: | Line 293: | ||
|} |
|} |
||
</div> |
</div> |
||
* Continued pricing momentum and volume growth in Mid-market and SME <sup>p. 14</sup> |
|||
* |
* Growing in lines of business with attractive margins while remaining focused on retention at AXA XL Insurance <sup>p. 14</sup> |
||
* |
* Growth supported by alternative capital <sup>p. 14</sup> |
||
* |
* Favorable pricing trends and strong growth in net new contracts (+1.7m in FY25) <sup>p. 14</sup> |
||
=== P&C | Delivering further margin expansion while enhancing reserve prudence === |
=== P&C | Delivering further margin expansion while enhancing reserve prudence === |
||
| Line 259: | Line 302: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Combined ratio |
|+ Combined ratio, FY24 vs FY25 <sup>p. 15</sup> |
||
! style="text-align:left" | % |
! style="text-align:left" | % |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|||
| style="text-align:left" | Combined ratio |
|||
| style="text-align:right" | 91.0 |
|||
| style="text-align:right" | 90.6 |
|||
|- |
|- |
||
| style="text-align:left" | Undiscounted CY loss ratio (ex Nat Cat) |
| style="text-align:left" | Undiscounted CY loss ratio (ex Nat Cat) |
||
| Line 283: | Line 330: | ||
| style="text-align:right" | -3.6 |
| style="text-align:right" | -3.6 |
||
| style="text-align:right" | -3.5 |
| style="text-align:right" | -3.5 |
||
|- |
|||
| style="text-align:left" | Combined ratio |
|||
| style="text-align:right" | 91.0 |
|||
| style="text-align:right" | 90.6 |
|||
|} |
|} |
||
</div> |
</div> |
||
* Better undiscounted current year loss ratio excluding Nat Cat from margin expansion in Commercial lines SME & mid-market business and Personal lines reflecting favorable pricing environment <sup>p. 15</sup> |
|||
* |
* Stable AXA XL Insurance margins at attractive levels reflecting disciplined cycle management <sup>p. 15</sup> |
||
* |
* Improvement in expense ratio reflecting the impact of efficiency measures, while continuing to invest in growth initiatives and technology <sup>p. 15</sup> |
||
* |
* Nat Cat charges below normalized load <sup>p. 15</sup> |
||
* |
* Lower reliance on prior year reserve development <sup>p. 15</sup> |
||
* Taking advantage of a good year to enhance reserve prudence <sup>p. 15</sup> |
|||
=== P&C | Earnings growth from higher underwriting and financial result === |
=== P&C | Earnings growth from higher underwriting and financial result === |
||
* Underwriting result improved from strong volume growth and improved all-year combined ratio while enhancing reserve prudence <sup>p. 16</sup> |
|||
* Investment income increased reflecting higher volumes and better reinvestment yields on fixed income assets <sup>p. 16</sup> |
|||
* Claims reserves discount unwind was higher, in line with guidance <sup>p. 16</sup> |
|||
* Forex impact was unfavorable notably due to USD depreciation vs. EUR <sup>p. 16</sup> |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Underlying earnings |
|+ Underlying earnings bridge, FY24 to FY25 <sup>p. 16</sup> |
||
! style="text-align:left" | EUR million |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | Underlying earnings |
! class="col-s" style="text-align:right" | Underlying earnings |
||
| Line 333: | Line 372: | ||
|} |
|} |
||
</div> |
</div> |
||
* (waterfall) '''Underlying earnings''' +9% at constant FX to EUR 5,872m (FY24: EUR 5,510m) <sup>p. 16</sup>: |
|||
* '''Underwriting result''' improved from strong volume growth and improved all-year combined ratio while enhancing reserve prudence <sup>p. 16</sup>. |
|||
* '''Investment income''' increased reflecting higher volumes and better reinvestment yields on fixed income assets <sup>p. 16</sup>. |
|||
* '''Unwind of discount''' of claims reserves was higher, in line with guidance <sup>p. 16</sup>. |
|||
* '''Forex impact''' was unfavorable notably due to USD depreciation vs. EUR <sup>p. 16</sup>. |
|||
* '''Underwriting result components''' include volume growth (+EUR 292m) and margin improvement (+EUR 189m) <sup>p. 16</sup>. |
|||
* '''Financial result components''' include investment income (+EUR 435m) and insurance finance expenses (-EUR 235m) <sup>p. 16</sup>. |
|||
* (waterfall) '''Underlying earnings bridge''' FY24→FY25: EUR 5,510m start → volume growth +EUR 292m → margin improvement +EUR 189m → investment income +EUR 435m → insurance finance expenses -EUR 235m → tax -EUR 169m → affiliates, FX & other -EUR 150m → EUR 5,872m end (+9% at constant FX) <sup>p. 16</sup>. |
|||
=== Life & Health | Strong growth in premiums, positive net flows === |
=== Life & Health | Strong growth in premiums, positive net flows === |
||
| Line 339: | Line 385: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ GWP & other revenues |
|+ Life GWP & other revenues, FY24 vs FY25 <sup>p. 17</sup> |
||
! style="text-align:left" | EUR billion unless otherwise mentioned |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | LFL Change |
! class="col-s" style="text-align:right" | LFL Change |
||
|- |
|||
| style="text-align:left" | '''Life''' |
|||
| style="text-align:right" | 34.5 |
|||
| style="text-align:right" | 37.5 |
|||
| style="text-align:right" | +9% |
|||
|- |
|- |
||
| style="text-align:left" | Protection |
| style="text-align:left" | Protection |
||
| Line 370: | Line 411: | ||
| style="text-align:right" | -7% |
| style="text-align:right" | -7% |
||
|- |
|- |
||
| style="text-align:left |
| style="text-align:left" | Employee benefits |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| style="text-align:right" | 12.9 |
| style="text-align:right" | 12.9 |
||
| style="text-align:right" | +4% |
| style="text-align:right" | +4% |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left; font-weight:bold" | Total |
||
| style="text-align:right" | |
| style="text-align:right; font-weight:bold" | 34.5 |
||
| style="text-align:right" | |
| style="text-align:right; font-weight:bold" | 37.5 |
||
| style="text-align:right" | + |
| style="text-align:right; font-weight:bold" | +9% |
||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
|+ Health GWP & other revenues, FY24 vs FY25 <sup>p. 17</sup> |
|||
! style="text-align:left" | EUR billion |
|||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
! class="col-s" style="text-align:right" | LFL Change |
|||
|- |
|- |
||
| style="text-align:left" | Individual |
| style="text-align:left" | Individual |
||
| Line 389: | Line 440: | ||
| style="text-align:right" | 8.5 |
| style="text-align:right" | 8.5 |
||
| style="text-align:right" | +4% |
| style="text-align:right" | +4% |
||
|- |
|||
| style="text-align:left; font-weight:bold" | Total |
|||
| style="text-align:right; font-weight:bold" | 17.5 |
|||
| style="text-align:right; font-weight:bold" | 19.0 |
|||
| style="text-align:right; font-weight:bold" | +5% |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 394: | Line 450: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Net flows |
|+ Net flows, FY24 vs FY25 <sup>p. 17</sup> |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|- |
||
| style="text-align:left |
| style="text-align:left" | Protection flows |
||
| style="text-align:right; font-weight:bold" | +1.5 |
|||
| style="text-align:right; font-weight:bold" | +5.4 |
|||
|- |
|||
| style="text-align:left" | Protection |
|||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| style="text-align:right" | +4.9 |
| style="text-align:right" | +4.9 |
||
|- |
|- |
||
| style="text-align:left" | Health |
| style="text-align:left" | Health flows |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| style="text-align:right" | +2.7 |
| style="text-align:right" | +2.7 |
||
|- |
|- |
||
| style="text-align:left" | Unit- |
| style="text-align:left" | Unit-linked flows |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| style="text-align:right" | +1.5 |
| style="text-align:right" | +1.5 |
||
|- |
|- |
||
| style="text-align:left" | Capital light |
| style="text-align:left" | Capital light flows |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| style="text-align:right" | +1.2 |
| style="text-align:right" | +1.2 |
||
|- |
|- |
||
| style="text-align:left" | Traditional G/A |
| style="text-align:left" | Traditional G/A flows |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| style="text-align:right" | -5.0 |
| style="text-align:right" | -5.0 |
||
|- |
|||
| style="text-align:left; font-weight:bold" | Total |
|||
| style="text-align:right; font-weight:bold" | +1.5 |
|||
| style="text-align:right; font-weight:bold" | +5.4 |
|||
|} |
|} |
||
</div> |
</div> |
||
=== Life & Health | Strong volume growth in Savings and Protection impacted by higher interest rates on discounting === |
=== Life & Health | Strong volume growth in Savings and Protection impacted by higher interest rates on discounting === |
||
* PVEP was impacted by higher interest rates on discounting despite strong growth in Life volumes <sup>p. 18</sup> |
|||
* NB CSM was driven by robust Savings & Protection sales, with reported growth impacted by higher interest rates for discounting of future profits <sup>p. 18</sup> |
|||
* NBV was broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France <sup>p. 18</sup> |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ PVEP by |
|+ PVEP by segment, FY24 vs FY25 <sup>p. 18</sup> |
||
! style="text-align:left" | EUR billion unless otherwise mentioned |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | LFL Change |
! class="col-s" style="text-align:right" | LFL Change |
||
|- |
|||
| style="text-align:left; font-weight:bold" | Total |
|||
| style="text-align:right; font-weight:bold" | 50.9 |
|||
| style="text-align:right; font-weight:bold" | 49.4 |
|||
| style="text-align:right; font-weight:bold" | -2% |
|||
|- |
|- |
||
| style="text-align:left" | Protection & Health |
| style="text-align:left" | Protection & Health |
||
| Line 449: | Line 496: | ||
| style="text-align:right" | -4% |
| style="text-align:right" | -4% |
||
|- |
|- |
||
| style="text-align:left" | Unit- |
| style="text-align:left" | Unit-linked |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| style="text-align:right" | 8.5 |
| style="text-align:right" | 8.5 |
||
| Line 463: | Line 510: | ||
| style="text-align:right" | 1.7 |
| style="text-align:right" | 1.7 |
||
| style="text-align:right" | -10% |
| style="text-align:right" | -10% |
||
|- |
|||
| style="text-align:left; font-weight:bold" | Total |
|||
| style="text-align:right; font-weight:bold" | 50.9 |
|||
| style="text-align:right; font-weight:bold" | 49.4 |
|||
| style="text-align:right; font-weight:bold" | -2% |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 468: | Line 520: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ NB CSM |
|+ NB CSM (pre-tax), FY24 vs FY25 <sup>p. 18</sup> |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 478: | Line 530: | ||
| style="text-align:right" | 2.2 |
| style="text-align:right" | 2.2 |
||
| style="text-align:right" | +3% |
| style="text-align:right" | +3% |
||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
|+ NBV (post-tax), FY24 vs FY25 <sup>p. 18</sup> |
|||
! style="text-align:left" | EUR billion |
|||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
! class="col-s" style="text-align:right" | LFL Change |
|||
|- |
|- |
||
| style="text-align:left" | NBV (post-tax) |
| style="text-align:left" | NBV (post-tax) |
||
| style="text-align:right" | 2.3 |
| style="text-align:right" | 2.3 |
||
| style="text-align:right" | 2.2 |
| style="text-align:right" | 2.2 |
||
| style="text-align:right" | |
| style="text-align:right" | stable |
||
|} |
|} |
||
</div> |
</div> |
||
* NBV margin 4.5% (FY24: 4.4%) <sup>p. 18</sup> |
|||
* '''PVEP''' was impacted by higher interest rates on discounting despite strong growth in Life volumes <sup>p. 18</sup>. |
|||
* '''NB CSM''' was driven by robust Savings & Protection sales, with reported growth impacted by higher interest rates for discounting of future profits <sup>p. 18</sup>. |
|||
* '''NBV''' was broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France <sup>p. 18</sup>. |
|||
* '''NBV margin''' improved to 4.5% (prior: 4.4%) <sup>p. 18</sup>. |
|||
=== Life & Health | Growth in new business driving Normalized CSM growth === |
=== Life & Health | Growth in new business driving Normalized CSM growth === |
||
| Line 491: | Line 557: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ CSM rollforward, FY24 to FY25 <sup>p. 19</sup> |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | CSM |
||
|- |
|- |
||
| style="text-align:left" | FY24 |
| style="text-align:left" | FY24 |
||
| style="text-align:right" | 33.6 |
| style="text-align:right" | 33.6 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | new business CSM |
||
| style="text-align:right" | +2.2 |
| style="text-align:right" | +2.2 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | underlying return on in-force |
||
| style="text-align:right" | +1.3 |
| style="text-align:right" | +1.3 |
||
|- |
|- |
||
| Line 507: | Line 573: | ||
| style="text-align:right" | -3.0 |
| style="text-align:right" | -3.0 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | economic variance |
||
| style="text-align:right" | +0.6 |
| style="text-align:right" | +0.6 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | operating variance |
||
| style="text-align:right" | -0.3 |
| style="text-align:right" | -0.3 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | affiliates, FX & other |
||
| style="text-align:right" | -1.4 |
| style="text-align:right" | -1.4 |
||
|- |
|- |
||
| Line 521: | Line 587: | ||
</div> |
</div> |
||
* '''Normalized CSM''' up by +2%, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates <sup>p. 19</sup> |
* '''Normalized CSM''' up by +2%, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates <sup>p. 19</sup>. |
||
* '''Economic variance''' |
* '''Economic variance''' reflected government spreads tightening and positive equity market returns <sup>p. 19</sup>. |
||
* '''Operating variance''' driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland <sup>p. 19</sup> |
* '''Operating variance''' was driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland <sup>p. 19</sup>. |
||
* '''FX impact''' mainly |
* '''FX impact''' was mainly driven by JPY and HKD depreciation <sup>p. 19</sup>. |
||
* FY24 |
* FY24 o/w Life EUR 25.8bn, Health EUR 7.7bn <sup>p. 19</sup>. |
||
* FY25 |
* FY25 o/w Life EUR 25.4bn, Health EUR 7.6bn <sup>p. 19</sup>. |
||
* '''Normalized CSM growth''' was +2% <sup>p. 19</sup>. |
|||
=== Life & Health | Strong momentum in both short-term and long-term business === |
=== Life & Health | Strong momentum in both short-term and long-term business === |
||
| Line 532: | Line 599: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Underlying earnings |
|+ Underlying earnings bridge, FY24 to FY25 <sup>p. 20</sup> |
||
! style="text-align:left" | EUR million |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | Underlying earnings |
! class="col-s" style="text-align:right" | Underlying earnings |
||
! class="col-s" style="text-align:right" | Short-term technical margin |
|||
! class="col-s" style="text-align:right" | Long-term result incl. CSM release |
|||
! class="col-s" style="text-align:right" | Financial result |
|||
! class="col-s" style="text-align:right" | Tax & others |
|||
|- |
|- |
||
| style="text-align:left" | FY24 |
| style="text-align:left" | FY24 |
||
| style="text-align:right" | 3,323 |
| style="text-align:right" | 3,323 |
||
| style="text-align:right" | 415 |
|||
| style="text-align:right" | 2,680 |
|||
| style="text-align:right" | 975 |
|||
| style="text-align:right" | -748 |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | short-term technical margin |
||
| style="text-align:right" | +60 |
| style="text-align:right" | +60 |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | long-term result incl. CSM release |
||
| style="text-align:right" | +156 |
| style="text-align:right" | +156 |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | financial result |
||
| style="text-align:right" | -11 |
| style="text-align:right" | -11 |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | tax, FX and others |
||
| style="text-align:right" | -27 |
| style="text-align:right" | -27 |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | FY25 |
| style="text-align:left" | FY25 |
||
| style="text-align:right" | 3,501 |
| style="text-align:right" | 3,501 |
||
| style="text-align:right" | 479 |
|||
| style="text-align:right" | 2,804 |
|||
| style="text-align:right" | 946 |
|||
| style="text-align:right" | -728 |
|||
|} |
|} |
||
</div> |
</div> |
||
* '''Short-term technical margin''' strong, reflecting underwriting and claims initiatives that more than offset the impact of legislative change on the recoverability of value added tax in Mexico (EUR -0.1bn) <sup>p. 20</sup> |
* '''Short-term technical margin''' was strong, reflecting underwriting and claims initiatives that more than offset the impact of legislative change on the recoverability of value added tax in Mexico (EUR -0.1bn) <sup>p. 20</sup>. |
||
* '''Long-term results''' higher from increase in CSM release (+8%) reflecting growth in reserve base, including from favorable equity market performance, and better margins <sup>p. 20</sup> |
* '''Long-term results''' were higher from an increase in CSM release (+8%) reflecting growth in reserve base, including from favorable equity market performance, and better margins <sup>p. 20</sup>. |
||
* |
* FY25 (+7% LFL) <sup>p. 20</sup>. |
||
* ''' |
* '''FY24 earnings mix''': short-term technical margin EUR 415m, long-term result incl. CSM release EUR 2,680m, financial result EUR 975m, tax & others -EUR 748m <sup>p. 20</sup>. |
||
* |
* '''FY25 earnings mix''': short-term technical margin EUR 479m, long-term result incl. CSM release EUR 2,804m, financial result EUR 946m, tax & others -EUR 728m <sup>p. 20</sup>. |
||
* '''Life underlying earnings''': FY24 EUR 2.6bn → FY25 EUR 2.7bn (+4% LFL) <sup>p. 20</sup>. |
|||
* '''Health underlying earnings''': FY24 EUR 0.7bn → FY25 EUR 0.8bn (+17% LFL) <sup>p. 20</sup>. |
|||
=== Growth in net income reflecting higher earnings & the gain from the sale of AXA IM === |
=== Growth in net income reflecting higher earnings & the gain from the sale of AXA IM === |
||
| Line 629: | Line 670: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Underlying EPS |
|+ Underlying EPS, FY24 vs FY25 <sup>p. 21</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | — |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
|||
! class="col-s" style="text-align:right" | Change |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Underlying EPS (reported basis) |
||
| style="text-align:right" | 3.59 |
|||
| style="text-align:right" | 3.86 |
|||
| style="text-align:right" | +8% |
|||
|- |
|||
| style="text-align:left" | from earnings growth |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | +6% |
| style="text-align:right" | +6% |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | from capital management |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | +3% |
| style="text-align:right" | +3% |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | from forex |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | -2% |
| style="text-align:right" | -2% |
||
|- |
|||
| style="text-align:left" | from temporary earnings dilution from AXA IM sale |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
| style="text-align:right" | -1% |
|||
|} |
|} |
||
</div> |
</div> |
||
* '''Non-financial flows''': EUR +2.1bn |
* '''Non-financial flows''': EUR +2.1bn in FY25 vs EUR -0.5bn in FY24, including EUR +2.2bn capital gains from AXA IM disposal <sup>p. 21</sup>. |
||
* '''Financial flows''': EUR -0.7bn in FY25 (including realized capital gains) vs EUR +0.3bn in FY24 <sup>p. 21</sup>. |
|||
* ''' |
* '''Net income''': EUR 9.8bn in FY25 vs EUR 7.9bn in FY24 (+26% at constant FX) <sup>p. 21</sup>. |
||
* ''' |
* '''Insurance business performance''': Strong performance from insurance businesses <sup>p. 21</sup>. |
||
* ''' |
* '''Holding costs''': Stable holding cost, expected to remain at current level in 2026 <sup>p. 21</sup>. |
||
* '''Net income drivers''': Higher net income mainly reflecting higher underlying earnings and the gain from the sale of AXA IM; lower financial flows reflecting unfavorable forex impact <sup>p. 21</sup>. |
|||
* '''Holding costs''': Stable holding cost, expected to remain at current level in 2026 <sup>p. 21</sup> |
|||
* |
* Includes <code>-1%</code> from temporary earnings dilution from AXA IM sale due to the timing of anti-dilutive share buyback <sup>p. 21</sup>. |
||
* '''Underlying EPS''': EUR 3.86 (+8% reported basis; FY24: EUR 3.59) <sup>p. 21</sup> |
|||
== FY25 Financial Performance == |
|||
** '''AXA IM dilution''': EPS includes -1% from temporary earnings dilution from AXA IM sale due to the timing of anti-dilutive share buyback <sup>p. 21</sup> |
|||
=== Shareholders' Equity === |
=== Shareholders' Equity === |
||
| Line 658: | Line 717: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Shareholders' equity and |
|+ Shareholders' equity and related metrics <sup>p. 22</sup> |
||
! style="text-align:left" | EUR billion unless otherwise mentioned |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 664: | Line 723: | ||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|- |
||
| style="text-align:left" | Shareholders' equity |
| style="text-align:left" | Shareholders' equity (Group share) |
||
| style="text-align:right" | 49.9 |
| style="text-align:right" | 49.9 |
||
| style="text-align:right" | 45.5 |
| style="text-align:right" | 45.5 |
||
| Line 679: | Line 738: | ||
| style="text-align:right" | -6.8 |
| style="text-align:right" | -6.8 |
||
|- |
|- |
||
| style="text-align:left" | SHE excl. OCI |
| style="text-align:left" | SHE (excl. OCI & undated subordinated debt) |
||
| style="text-align:right" | 53.2 |
| style="text-align:right" | 53.2 |
||
| style="text-align:right" | 47.0 |
| style="text-align:right" | 47.0 |
||
| Line 698: | Line 757: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Shareholders' equity bridge, FY24 |
|+ Shareholders' equity bridge, FY24 to FY25 <sup>p. 22</sup> |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Value |
||
! class="col-s" style="text-align:right" | HY25 to FY25 |
|||
|- |
|- |
||
| style="text-align:left" | Opening SHE |
| style="text-align:left" | Opening SHE |
||
| style="text-align:right" | 49.9 |
| style="text-align:right" | 49.9 |
||
| style="text-align:right" | 45.5 |
|||
|- |
|- |
||
| style="text-align:left" | Change in Net OCI |
| style="text-align:left" | Change in Net OCI |
||
| style="text-align:right" | +1.3 |
| style="text-align:right" | +1.3 |
||
| style="text-align:right" | +0.4 |
|||
|- |
|- |
||
| style="text-align:left" | Net income |
| style="text-align:left" | Net income |
||
| style="text-align:right" | +9.8 |
| style="text-align:right" | +9.8 |
||
| style="text-align:right" | +5.9 |
|||
|- |
|- |
||
| style="text-align:left" | Dividend |
| style="text-align:left" | Dividend |
||
| style="text-align:right" | -4.6 |
| style="text-align:right" | -4.6 |
||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Annual share buyback |
| style="text-align:left" | Annual share buyback |
||
| style="text-align:right" | -1.2 |
| style="text-align:right" | -1.2 |
||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Anti-dilutive buyback |
| style="text-align:left" | Anti-dilutive share buyback |
||
| style="text-align:right" | -3.5 |
|||
| style="text-align:right" | -3.5 |
| style="text-align:right" | -3.5 |
||
|- |
|- |
||
| style="text-align:left" | Undated subordinated debt |
| style="text-align:left" | Undated subordinated debt |
||
| style="text-align:right" | -0.3 |
| style="text-align:right" | -0.3 |
||
| style="text-align:right" | -1.2 |
|||
|- |
|- |
||
| style="text-align:left" | Forex |
| style="text-align:left" | Forex |
||
| style="text-align:right" | -3.5 |
| style="text-align:right" | -3.5 |
||
| style="text-align:right" | -0.1 |
|||
|- |
|- |
||
| style="text-align:left" | Other |
| style="text-align:left" | Other |
||
| style="text-align:right" | -0.6 |
| style="text-align:right" | -0.6 |
||
|- |
|||
| style="text-align:left" | Closing SHE |
|||
| style="text-align:right" | 47.2 |
|||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
|+ Shareholders' equity bridge, HY25 to FY25 <sup>p. 22</sup> |
|||
! style="text-align:left" | EUR billion |
|||
! class="col-s" style="text-align:right" | Value |
|||
|- |
|||
| style="text-align:left" | Opening SHE |
|||
| style="text-align:right" | 45.5 |
|||
|- |
|||
| style="text-align:left" | Change in Net OCI |
|||
| style="text-align:right" | +0.4 |
|||
|- |
|||
| style="text-align:left" | Net income |
|||
| style="text-align:right" | +5.9 |
|||
|- |
|||
| style="text-align:left" | Anti-dilutive share buyback |
|||
| style="text-align:right" | -3.5 |
|||
|- |
|||
| style="text-align:left" | Undated subordinated debt |
|||
| style="text-align:right" | -1.2 |
|||
|- |
|||
| style="text-align:left" | Forex |
|||
| style="text-align:right" | -0.1 |
|||
|- |
|||
| style="text-align:left" | Other |
|||
| style="text-align:right" | +0.3 |
| style="text-align:right" | +0.3 |
||
|- |
|- |
||
| style="text-align:left" | Closing SHE |
| style="text-align:left" | Closing SHE |
||
| style="text-align:right" | 47.2 |
|||
| style="text-align:right" | 47.2 |
| style="text-align:right" | 47.2 |
||
|} |
|} |
||
| Line 749: | Line 829: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Net |
|+ Net cash remittance <sup>p. 23</sup> |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|- |
||
| style="text-align:left" | Net |
| style="text-align:left" | Net cash remittance |
||
| style="text-align:right" | 7.7 |
| style="text-align:right" | 7.7 |
||
| style="text-align:right" | 7.5 |
| style="text-align:right" | 7.5 |
||
|- |
|- |
||
| style="text-align:left" | Ordinary |
| style="text-align:left" | Ordinary remittance |
||
| style="text-align:right" | 7.1 |
| style="text-align:right" | 7.1 |
||
| style="text-align:right" | 7.5 |
| style="text-align:right" | 7.5 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | In-force treaties proceeds |
||
| style="text-align:right" | 0.6 |
| style="text-align:right" | 0.6 |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|- |
|||
| style="text-align:left" | Remittance ratio |
|||
| style="text-align:right" | 82% |
|||
| style="text-align:right" | 82% |
|||
|} |
|} |
||
</div> |
</div> |
||
* In-force treaties proceeds in FY24 related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe. |
|||
* Remittance ratio: 82% in FY25 (FY24: 82%) |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Holding cash bridge <sup>p. 23</sup> |
|+ Holding cash bridge, FY24 to FY25 <sup>p. 23</sup> |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Value |
||
|- |
|- |
||
| style="text-align:left" | FY24 Cash position |
| style="text-align:left" | FY24 Cash position |
||
| style="text-align:right" | 4.0 |
| style="text-align:right" | 4.0 |
||
|- |
|- |
||
| style="text-align:left" | Net cash remittance |
| style="text-align:left" | Net cash remittance |
||
| style="text-align:right" | +7.5 |
| style="text-align:right" | +7.5 |
||
|- |
|- |
||
| Line 790: | Line 869: | ||
| style="text-align:right" | -1.2 |
| style="text-align:right" | -1.2 |
||
|- |
|- |
||
| style="text-align:left" | Anti-dilutive buyback |
| style="text-align:left" | Anti-dilutive share buyback |
||
| style="text-align:right" | -3.5 |
| style="text-align:right" | -3.5 |
||
|- |
|- |
||
| style="text-align:left" | Holding costs |
| style="text-align:left" | Holding costs |
||
| style="text-align:right" | -1.3 |
| style="text-align:right" | -1.3 |
||
|- |
|- |
||
| Line 806: | Line 885: | ||
|} |
|} |
||
</div> |
</div> |
||
* Holding costs include interest expenses. |
|||
* Anti-dilutive share buyback following the sale of AXA IM. |
|||
=== Solvency II at 224% === |
=== Solvency II at 224% === |
||
| Line 813: | Line 895: | ||
|+ Solvency II walk, FY24 to FY25 <sup>p. 24</sup> |
|+ Solvency II walk, FY24 to FY25 <sup>p. 24</sup> |
||
! style="text-align:left" | EUR billion unless otherwise mentioned |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | EOF |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | SCR |
||
! class="col-s" style="text-align:right" | Solvency II ratio ( |
! class="col-s" style="text-align:right" | Solvency II ratio (%) |
||
|- |
|- |
||
| style="text-align:left" | FY24 |
| style="text-align:left" | FY24 |
||
| Line 842: | Line 924: | ||
| style="text-align:right" | +4 |
| style="text-align:right" | +4 |
||
|- |
|- |
||
| style="text-align:left" | Dividend & |
| style="text-align:left" | Dividend & buyback |
||
| style="text-align:right" | -6.0 |
| style="text-align:right" | -6.0 |
||
| style="text-align:right" | 0.0 |
| style="text-align:right" | 0.0 |
||
| style="text-align:right" | -24 |
| style="text-align:right" | -24 |
||
|- |
|- |
||
| style="text-align:left" | Management actions |
| style="text-align:left" | Management actions |
||
| style="text-align:right" | -0.1 |
| style="text-align:right" | -0.1 |
||
| style="text-align:right" | -0.2 |
| style="text-align:right" | -0.2 |
||
| Line 858: | Line 940: | ||
|} |
|} |
||
</div> |
</div> |
||
* Dividend & buyback comprises foreseeable dividends of EUR -4.8bn and provision for annual share buyback for 2026 of EUR -1.25bn. |
|||
* Management actions include debt & other. |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
| Line 880: | Line 965: | ||
| style="text-align:right" | -4 |
| style="text-align:right" | -4 |
||
|- |
|- |
||
| style="text-align:left" | Listed Equity +25% |
| style="text-align:left" | Listed Equity +25% (excl. PE & Infra) |
||
| style="text-align:right" | -1 |
| style="text-align:right" | -1 |
||
|- |
|- |
||
| style="text-align:left" | Listed Equity -25% |
| style="text-align:left" | Listed Equity -25% (excl. PE & Infra) |
||
| style="text-align:right" | +2 |
| style="text-align:right" | +2 |
||
|- |
|- |
||
| Line 896: | Line 981: | ||
|} |
|} |
||
</div> |
</div> |
||
* (waterfall) '''Eligible Own Funds''': FY24 EUR 55.9bn → Regulatory & model changes EUR +0.2bn → Normalized capital generation EUR +8.8bn → Operating variance EUR -0.4bn → Economic variance & FX EUR -2.1bn → Dividend & annual share buyback EUR -6.0bn (comprising foreseeable dividends of EUR -4.8bn and provision for annual share buyback for 2026 of EUR -1.25bn) → Management actions, debt & other EUR -0.1bn → FY25 EUR 56.4bn <sup>p. 24</sup> |
|||
* Euro Sovereign spreads +50bps assumes 50bps spread widening vs Euro swap curve. |
|||
* '''Credit migration''': -4pts (assumes 20% of corporate bonds/private debt held are downgraded by one full letter/3 notches) <sup>p. 24</sup> |
|||
* Credit migration assumes 20% of corporate bonds held are downgraded by one full letter / 3 notches. |
|||
=== Solvency II -impact of the end of grandfathering period and Solvency II revision === |
=== Solvency II -impact of the end of grandfathering period and Solvency II revision === |
||
* '''Solvency II ratio''' as of December 31, 2025: 224% <sup>p. 25</sup> |
|||
<div style="overflow-x:auto"> |
|||
* '''Grandfathering period end''': Impact of -10pts to 215% on January 1, 2026 <sup>p. 25</sup> |
|||
{| class="wikitable fintable" |
|||
** EUR 2.4bn grandfathered debt is no longer eligible as capital from January 1, 2026 <sup>p. 25</sup> |
|||
* '''Solvency II revision''': Estimated impact of +17pts (to come into effect in 1Q27) <sup>p. 25</sup> |
|||
! style="text-align:left" | Item |
|||
** No change expected in organic capital generation <sup>p. 25</sup> |
|||
! class="col-s" style="text-align:right" | Value |
|||
** Additional capital flexibility <sup>p. 25</sup> |
|||
|- |
|||
** Estimated based on SCR and EOF under Solvency II as of January 1, 2026, as if the revision had come into force on that date <sup>p. 25</sup> |
|||
| style="text-align:left" | Solvency II ratio as of December 31, 2025 |
|||
| style="text-align:right" | 224% |
|||
|- |
|||
| style="text-align:left" | Grandfathering impact on January 1, 2026 |
|||
| style="text-align:right" | -10pts |
|||
|- |
|||
| style="text-align:left" | Solvency II ratio after grandfathering |
|||
| style="text-align:right" | 215% |
|||
|- |
|||
| style="text-align:left" | Solvency II revision estimated impact (as of January 1, 2026) |
|||
| style="text-align:right" | +17pts |
|||
|} |
|||
</div> |
|||
* EUR 2.4bn grandfathered debt is no longer eligible as capital from January 1, 2026 |
|||
* No change expected in organic capital generation |
|||
* Additional capital flexibility |
|||
* '''Solvency II revision''': +17pts estimated impact to come into effect in 1Q27 (estimated as of January 1, 2026) <sup>p. 25</sup> |
|||
=== Thomas Buberl, Group CEO conclusion === |
=== Thomas Buberl, Group CEO conclusion === |
||
* ''' |
* '''Section divider''' featuring Thomas Buberl, Group CEO <sup>p. 26</sup> |
||
=== Conclusion === |
=== Conclusion === |
||
* '''Record results''' |
* '''Record results''' at the top end of the target range while enhancing reserve prudence <sup>p. 27</sup> |
||
* '''All businesses''' in excellent shape, delivering strong growth and profitability <sup>p. 27</sup> |
* '''All businesses''' in excellent shape, delivering strong growth and profitability <sup>p. 27</sup> |
||
* '''Diversified franchise''' well-positioned to capture future growth opportunities <sup>p. 27</sup> |
* '''Diversified franchise''' well-positioned to capture future growth opportunities <sup>p. 27</sup> |
||
| Line 938: | Line 1,008: | ||
=== February 26, 2026 Q&A Full Year 2025 earnings === |
=== February 26, 2026 Q&A Full Year 2025 earnings === |
||
* ''' |
* '''Section divider''' for Q&A session on February 26, 2026 <sup>p. 28</sup> |
||
=== AXA Investor Relations | Keep in touch === |
=== AXA Investor Relations | Keep in touch === |
||
* '''Meet our management''' |
* '''Meet our management''' event calendar: |
||
** March: Roadshows in Europe and US <sup>p. 29</sup> |
** March: Roadshows in Europe and US <sup>p. 29</sup> |
||
** May 5: 1Q25 Activity Indicators in Paris <sup>p. 29</sup> |
** May 5: 1Q25 Activity Indicators in Paris <sup>p. 29</sup> |
||
| Line 949: | Line 1,019: | ||
** July 31: HY26 Earnings Release in Paris <sup>p. 29</sup> |
** July 31: HY26 Earnings Release in Paris <sup>p. 29</sup> |
||
** September 21: AXA Investor Day in London <sup>p. 29</sup> |
** September 21: AXA Investor Day in London <sup>p. 29</sup> |
||
* '''Contact us''' details |
* '''Contact us''' details: Investor Relations phone +33 1 40 75 48 42; email investor.relations@axa.com <sup>p. 29</sup> |
||
* '''Follow us''' website: www.axa.com <sup>p. 29</sup> |
|||
** Email: investor.relations@axa.com <sup>p. 29</sup> |
|||
* '''Follow us''' online: |
|||
** Website: www.axa.com <sup>p. 29</sup> |
|||
== Appendices == |
== Appendices == |
||
* '''Section divider''' for |
* '''Section divider''' for appendices <sup>p. 30</sup> |
||
<div style="overflow-x:auto"> |
|||
* '''Debt and Invested Assets''' p.31 <sup>p. 31</sup> |
|||
{| class="wikitable fintable" |
|||
* '''Additional P&C disclosures''' p.36 <sup>p. 31</sup> |
|||
|+ Additional disclosures by topic and page <sup>p. 31</sup> |
|||
! style="text-align:left" | Topic |
|||
* '''Sustainability''' p.44 <sup>p. 31</sup> |
|||
! class="col-s" style="text-align:right" | Page |
|||
|- |
|||
| style="text-align:left" | Debt and Invested Assets |
|||
| style="text-align:right" | 31 |
|||
|- |
|||
| style="text-align:left" | Additional P&C disclosures |
|||
| style="text-align:right" | 36 |
|||
|- |
|||
| style="text-align:left" | Additional IFRS17 disclosures |
|||
| style="text-align:right" | 41 |
|||
|- |
|||
| style="text-align:left" | Sustainability |
|||
| style="text-align:right" | 44 |
|||
|} |
|||
</div> |
|||
=== Gross financial debt and maturity breakdown as of December 31st, 2025 === |
=== Gross financial debt and maturity breakdown as of December 31st, 2025 === |
||
* (stacked bar) '''Gross financial debt''': |
|||
* '''Debt gearing''' was 20.6% in FY24 and 22.3% in FY25 <sup>p. 32</sup> |
|||
** '''FY24''': EUR 19.2bn total (Tier 1: EUR 4.8bn, Tier 2: EUR 10.8bn, Senior debt: EUR 3.5bn); debt gearing at 20.6% <sup>p. 32</sup> |
|||
* (stacked bar) '''Gross financial debt''' (nominal debt): |
|||
** ''' |
** '''FY25''': EUR 20.3bn total (Tier 1: EUR 4.6bn, Tier 2: EUR 12.2bn, Senior debt: EUR 3.5bn); debt gearing at 22.3% <sup>p. 32</sup> |
||
** ''' |
** '''Jan 1st 2026''' (End of the grandfathering period): EUR 20.3bn total (Tier 1: EUR 3.2bn, Tier 2: EUR 11.3bn, Senior debt: EUR 5.8bn, of which EUR 0.4bn redeemed in Jan 2026) <sup>p. 32</sup> |
||
** '''Jan 1st 2026''' (End of the grandfathering period): EUR 20.3bn total (Tier 1: EUR 3.2bn, Tier 2: EUR 11.3bn, Senior debt: EUR 5.8bn; o/w EUR 0.4bn redeemed in Jan 2026) <sup>p. 32</sup> |
|||
* (bar chart) '''Contractual maturity breakdown''': |
* (bar chart) '''Contractual maturity breakdown''': |
||
** '''2028''': EUR 0.5bn (Senior debt) <sup>p. 32</sup> |
** '''2028''': EUR 0.5bn (Senior debt) <sup>p. 32</sup> |
||
| Line 977: | Line 1,058: | ||
** '''≥2040''': EUR 11.3bn total (Tier 2: EUR 10.8bn, Senior debt: EUR 0.5bn) <sup>p. 32</sup> |
** '''≥2040''': EUR 11.3bn total (Tier 2: EUR 10.8bn, Senior debt: EUR 0.5bn) <sup>p. 32</sup> |
||
** '''Undated''': EUR 5.3bn total (Tier 1: EUR 4.6bn, Tier 2: EUR 0.7bn) <sup>p. 32</sup> |
** '''Undated''': EUR 5.3bn total (Tier 1: EUR 4.6bn, Tier 2: EUR 0.7bn) <sup>p. 32</sup> |
||
** ''' |
** '''Of which Grandfathered debt (Contractual)''': Tier 1 Undated: EUR 1.4bn; Tier 2 2030: EUR 0.7bn, ≥2040: EUR 0.2bn <sup>p. 32</sup> |
||
* (bar chart) '''Economic maturity breakdown''' |
* (bar chart) '''Economic maturity breakdown''': |
||
** '''2026''': EUR 0.1bn (Tier 1) <sup>p. 32</sup> |
** '''2026''': EUR 0.1bn (Tier 1) <sup>p. 32</sup> |
||
** '''2027''': EUR 2.4bn (Tier 2) <sup>p. 32</sup> |
** '''2027''': EUR 2.4bn (Tier 2) <sup>p. 32</sup> |
||
| Line 984: | Line 1,065: | ||
** '''2029''': EUR 2.0bn (Tier 2) <sup>p. 32</sup> |
** '''2029''': EUR 2.0bn (Tier 2) <sup>p. 32</sup> |
||
** '''2030''': EUR 0.9bn total (Tier 2: EUR 0.7bn, Senior debt: EUR 0.2bn) <sup>p. 32</sup> |
** '''2030''': EUR 0.9bn total (Tier 2: EUR 0.7bn, Senior debt: EUR 0.2bn) <sup>p. 32</sup> |
||
** '''2031-2039''': EUR 1. |
** '''2031-2039''': EUR 1.5bn total (Tier 1: EUR 0.4bn, Tier 2: EUR 1.1bn) <sup>p. 32</sup> |
||
** '''≥2040''': EUR 0.5bn (Senior debt) <sup>p. 32</sup> |
** '''≥2040''': EUR 0.5bn (Senior debt) <sup>p. 32</sup> |
||
** '''Undated''': EUR 4.7bn total (Tier 1: EUR 4.0bn, Tier 2: EUR 0.7bn) <sup>p. 32</sup> |
** '''Undated''': EUR 4.7bn total (Tier 1: EUR 4.0bn, Tier 2: EUR 0.7bn) <sup>p. 32</sup> |
||
** ''' |
** '''Of which Grandfathered debt (Economic)''': Tier 1: 2026: EUR 0.1bn, 2028: EUR 0.1bn, 2031-2039: EUR 0.4bn, Undated: EUR 0.8bn; Tier 2: 2030: EUR 0.7bn, ≥2040: EUR 0.2bn <sup>p. 32</sup> |
||
* In January 2026, AXA called the remaining T2 GF GBP 139m due 2054 callable 2034 5.625% issued January 2014 and the T1 GF EUR 250m perpetual callable 2010 floating issued January 2005 <sup>p. 32</sup>. |
* '''Redemption actions''': In January 2026, AXA called the remaining T2 GF GBP 139m due 2054 callable 2034 5.625% issued January 2014, and the T1 GF EUR 250m perpetual callable 2010 floating issued January 2005 <sup>p. 32</sup>. |
||
* '''Economic maturity definition''': Takes into account the first date of step-up calls on institutionally placed subordinated debt; Solvency II RT1 debt has no step-up, so its undated nature is retained <sup>p. 32</sup>. |
|||
=== General Account invested assets === |
=== General Account invested assets === |
||
| Line 994: | Line 1,076: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Total General Account invested assets |
|+ FY25 Total General Account invested assets <sup>p. 33</sup> |
||
! style="text-align:left" | EUR billion unless otherwise mentioned |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | Value |
|||
! class="col-s" style="text-align:right" | Share |
! class="col-s" style="text-align:right" | Share |
||
|- |
|- |
||
| Line 1,002: | Line 1,085: | ||
| style="text-align:right" | 77% |
| style="text-align:right" | 77% |
||
|- |
|- |
||
| style="text-align:left |
| style="text-align:left" | Government bonds |
||
| style="text-align:right" | 167 |
| style="text-align:right" | 167 |
||
| style="text-align:right" | 37% |
| style="text-align:right" | 37% |
||
|- |
|- |
||
| style="text-align:left |
| style="text-align:left" | Corporate bonds and loans |
||
| style="text-align:right" | 121 |
| style="text-align:right" | 121 |
||
| style="text-align:right" | 27% |
| style="text-align:right" | 27% |
||
|- |
|- |
||
| style="text-align:left |
| style="text-align:left" | Other fixed income |
||
| style="text-align:right" | 56 |
| style="text-align:right" | 56 |
||
| style="text-align:right" | 13% |
| style="text-align:right" | 13% |
||
| Line 1,038: | Line 1,121: | ||
| style="text-align:right" | 0% |
| style="text-align:right" | 0% |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left; font-weight:bold" | Total Insurance Invested Assets |
||
| style="text-align:right" | |
| style="text-align:right; font-weight:bold" | 450 |
||
| style="text-align:right" | |
| style="text-align:right; font-weight:bold" | 100% |
||
|} |
|} |
||
</div> |
</div> |
||
* Total General Account invested assets in FY25: EUR 450bn with a duration gap at -0.4 year <sup>p. 33</sup> |
|||
* Total General Account invested assets: EUR 450bn total, with a duration gap at -0.4 year |
|||
* Other fixed income includes Asset Backed Securities of EUR 25bn, Residential Loans of EUR 16bn, Commercial & Agricultural Loans of EUR 7bn, and Agency Pools of EUR 8bn <sup>p. 33</sup> |
|||
* Other fixed income includes Asset Backed Securities (EUR 25bn), Residential Loans (EUR 16bn), Commercial & Agricultural Loans (EUR 7bn), and Agency Pools (EUR 8bn) |
|||
* Listed equities includes hedges; listed equities excluding hedges at EUR 14bn <sup>p. 33</sup> |
|||
* Listed equities includes hedges (listed equities excluding hedges at EUR 14bn) |
|||
* Private equity and hedge funds includes Private Equity of EUR 17bn, Hedge Funds of EUR 5bn, and Non-listed Equities of EUR 1bn <sup>p. 33</sup> |
|||
* Private equity and hedge funds includes Private Equity (EUR 17bn), Hedge Funds (EUR 5bn), and Non-listed Equities (EUR 1bn) |
|||
=== Structured and Private Credit assets === |
=== Structured and Private Credit assets === |
||
| Line 1,054: | Line 1,138: | ||
|+ Structured and Private Credit Assets <sup>p. 34</sup> |
|+ Structured and Private Credit Assets <sup>p. 34</sup> |
||
! style="text-align:left" | EUR billion unless otherwise mentioned |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | Value |
|||
! class="col-s" style="text-align:right" | % of total G/A portfolio |
! class="col-s" style="text-align:right" | % of total G/A portfolio |
||
|- |
|- |
||
| Line 1,080: | Line 1,165: | ||
| style="text-align:right" | 0% |
| style="text-align:right" | 0% |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left; font-weight:bold" | Total Structured and Private Credit Assets |
||
| style="text-align:right" | |
| style="text-align:right; font-weight:bold" | 69 |
||
| style="text-align:right" | |
| style="text-align:right; font-weight:bold" | 15% |
||
|} |
|} |
||
</div> |
</div> |
||
* Residential Mortgages includes EUR 6bn Dutch mortgages (NHG guaranteed) and EUR 10bn self-originated mortgages in Switzerland (56% LTV) and Germany (45% LTV) <sup>p. 34</sup> |
|||
* Residential Mortgages: EUR 6bn Dutch mortgages, NHG guaranteed; EUR 10bn self-originated mortgages in Switzerland (56% LTV) and Germany (45% LTV) |
|||
* CLO & ABS: 91% senior CLOs with circa 40% subordination (100% rated AAA-A and 92% rated AAA-AA) <sup>p. 34</sup> |
|||
* CLO & ABS: 91% senior CLOs with circa 40% subordination (100% rated AAA-A and 92% rated AAA-AA) |
|||
* Infrastructure debt: skewed towards resilient industries (Telecom, Utilities, Transport) <sup>p. 34</sup> |
|||
* Infrastructure debt: skewed towards resilient industries (Telecom, Utilities, Transport) |
|||
* CRE debt: strong sector diversification (mainly logistics, residential, and retail), mostly in Europe, and circa 60% LTV <sup>p. 34</sup> |
|||
* CRE debt: strong sector diversification (mainly logistics, residential and retail), mostly in Europe, and circa 60% LTV |
|||
* Mid-Market lending: strong diversification with EUR 8m average ticket; investments through SMAs with strict underwriting guidelines (senior secured, covenants, restrictions on asset sales and sector allocation) <sup>p. 34</sup> |
|||
* Mid-Market lending: strong diversification with EUR 8m average ticket; investments through SMAs with strict underwriting guidelines: senior secured, covenants, restrictions on asset sales and sector allocation |
|||
* Total Structured and Private Credit Assets: o/w 54% participating <sup>p. 34</sup> |
|||
* Total Structured and Private Credit Assets: 54% participating |
|||
=== Investment portfolio | Fixed Income reinvestment === |
=== Investment portfolio | Fixed Income reinvestment === |
||
| Line 1,099: | Line 1,185: | ||
! style="text-align:left" | EUR billion unless otherwise mentioned |
! style="text-align:left" | EUR billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | Share |
! class="col-s" style="text-align:right" | Share |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Yield |
||
|- |
|||
| style="text-align:left" | Government bonds & related |
|||
| style="text-align:right" | 32% |
|||
| style="text-align:right" | AA |
|||
|- |
|- |
||
| style="text-align:left" | Investment grade credit |
| style="text-align:left" | Investment grade credit |
||
| style="text-align:right" | 40% |
| style="text-align:right" | 40% |
||
| style="text-align:right" | |
| style="text-align:right" | — |
||
|- |
|||
| style="text-align:left" | Government bonds & related |
|||
| style="text-align:right" | 32% |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | ABS/CLO/IG fund financing |
| style="text-align:left" | ABS/CLO/IG fund financing |
||
| Line 1,116: | Line 1,202: | ||
| style="text-align:right" | 7% |
| style="text-align:right" | 7% |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
|+ FY25 Fixed Income Reinvestment Yield <sup>p. 35</sup> |
|||
! style="text-align:left" | — |
|||
! class="col-s" style="text-align:right" | Yield |
|||
|- |
|- |
||
| style="text-align:left" | Public fixed income |
| style="text-align:left" | Public fixed income |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | 3.5% |
| style="text-align:right" | 3.5% |
||
|- |
|- |
||
| style="text-align:left" | Private & Structured fixed income |
| style="text-align:left" | Private & Structured fixed income |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | 4.7% |
| style="text-align:right" | 4.7% |
||
|- |
|- |
||
| style="text-align:left; font-weight:bold" | Total fixed income |
| style="text-align:left; font-weight:bold" | Total fixed income |
||
| style="text-align:right; font-weight:bold" | — |
|||
| style="text-align:right; font-weight:bold" | 3.9% |
| style="text-align:right; font-weight:bold" | 3.9% |
||
|} |
|} |
||
</div> |
</div> |
||
* Reinvestment highlights: |
|||
* Fixed income reinvestment of EUR 57bn invested at 3.9% with an average duration of 9 years <sup>p. 35</sup> |
|||
* |
** EUR 57bn fixed income invested at 3.9% <sup>p. 35</sup> |
||
** Average duration of 9 years <sup>p. 35</sup> |
|||
* Asset allocation shift shows a gradual shift from alternative total return assets to Private & Structured credit <sup>p. 35</sup> |
|||
** Includes EUR 19.7bn of Private & Structured Credit invested at 4.7% (CLOs, ABS, Infra & CRE debt, Fund financing and Private HY) <sup>p. 35</sup> |
|||
** Gradual shift from alternative total return assets to Private & Structured credit <sup>p. 35</sup> |
|||
* '''Additional P&C disclosures''' |
* '''Additional P&C disclosures''' is covered on page 36 <sup>p. 36</sup>. |
||
* |
* Other sections in the appendix include Debt and Invested Assets on page 31, Additional IFRS17 disclosures on page 41, and Sustainability on page 44 <sup>p. 36</sup>. |
||
* '''Additional IFRS17 disclosures''' featured on page 41 <sup>p. 36</sup> |
|||
* '''Sustainability''' featured on page 44 <sup>p. 36</sup> |
|||
=== AXA XL Insurance | Large Commercial & Specialty business === |
=== AXA XL Insurance | Large Commercial & Specialty business === |
||
| Line 1,149: | Line 1,230: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ FY25 GWP |
|+ FY25 GWP breakdown <sup>p. 37</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | USD billion unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | GWP by line |
! class="col-s" style="text-align:right" | GWP by line |
||
! class="col-s" style="text-align:right" | GWP by geography |
! class="col-s" style="text-align:right" | GWP by geography |
||
|- |
|- |
||
| Line 1,166: | Line 1,247: | ||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|- |
|- |
||
| style="text-align:left" | Professional lines |
| style="text-align:left" | Professional lines (including Cyber) |
||
| style="text-align:right" | 17% |
| style="text-align:right" | 17% |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| Line 1,184: | Line 1,265: | ||
</div> |
</div> |
||
* |
* Market position: Top 3 globally in Multinational Programs, Marine, and Fine Art & Specie <sup>p. 37</sup>. |
||
* (bubble chart) Cycle management: Property has the highest profitability and highest ex-price growth; Specialty has medium profitability and medium ex-price growth; Casualty has medium-low profitability and medium-low ex-price growth; Professional lines has the lowest profitability and lowest ex-price growth <sup>p. 37</sup>. |
|||
* Market positions leading across lines, ranking Top 3 globally in Multinational Programs, Marine, and Fine Art & Specie <sup>p. 37</sup> |
|||
* Cycle management active to deliver consistent profitability <sup>p. 37</sup> |
|||
* (bubble chart) Profitability vs growth (ex-price growth %): |
|||
** Professional lines: Lowest profitability, lowest ex-price growth <sup>p. 37</sup> |
|||
** Casualty: Medium-low profitability, medium-low ex-price growth <sup>p. 37</sup> |
|||
** Specialty: Medium profitability, medium ex-price growth <sup>p. 37</sup> |
|||
** Property: Highest profitability, highest ex-price growth <sup>p. 37</sup> |
|||
=== P&C | Focus on Reserves === |
=== P&C | Focus on Reserves === |
||
| Line 1,197: | Line 1,272: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Claims and technical reserves |
|+ Claims and technical reserves ratios by IFRS basis <sup>p. 38</sup> |
||
! style="text-align:left" | % |
! style="text-align:left" | % |
||
! class="col-s" style="text-align:right" | FY18 |
! class="col-s" style="text-align:right" | FY18 |
||
| Line 1,208: | Line 1,283: | ||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|- |
||
| style="text-align:left" | Claims reserves ratio IFRS4 |
| style="text-align:left" | Claims reserves ratio (IFRS4) |
||
| style="text-align:right" | 179% |
| style="text-align:right" | 179% |
||
| style="text-align:right" | 185% |
| style="text-align:right" | 185% |
||
| Line 1,218: | Line 1,293: | ||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|- |
|- |
||
| style="text-align:left" | Claims reserves ratio IFRS17 |
| style="text-align:left" | Claims reserves ratio (IFRS17) |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| Line 1,228: | Line 1,303: | ||
| style="text-align:right" | 175% |
| style="text-align:right" | 175% |
||
|- |
|- |
||
| style="text-align:left" | Technical reserves ratio IFRS4 |
| style="text-align:left" | Technical reserves ratio (IFRS4) |
||
| style="text-align:right" | 213% |
| style="text-align:right" | 213% |
||
| style="text-align:right" | 227% |
| style="text-align:right" | 227% |
||
| Line 1,238: | Line 1,313: | ||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|- |
|- |
||
| style="text-align:left" | Technical reserves ratio IFRS17 |
| style="text-align:left" | Technical reserves ratio (IFRS17) |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| Line 1,254: | Line 1,329: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Reinsurance capacity and retention by peril <sup>p. 39</sup> |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | Capacity |
! class="col-s" style="text-align:right" | Capacity |
||
| Line 1,261: | Line 1,336: | ||
| style="text-align:left" | EU Windstorm |
| style="text-align:left" | EU Windstorm |
||
| style="text-align:right" | 4.0 |
| style="text-align:right" | 4.0 |
||
| style="text-align:right" | |
| style="text-align:right" | 600m |
||
|- |
|- |
||
| style="text-align:left" | Europe Flood |
| style="text-align:left" | Europe Flood |
||
| style="text-align:right" | 2.1 |
| style="text-align:right" | 2.1 |
||
| style="text-align:right" | |
| style="text-align:right" | 450m |
||
|- |
|- |
||
| style="text-align:left" | Europe Earthquake |
| style="text-align:left" | Europe Earthquake |
||
| style="text-align:right" | 2.1 |
| style="text-align:right" | 2.1 |
||
| style="text-align:right" | |
| style="text-align:right" | 400m |
||
|- |
|- |
||
| style="text-align:left" | NA Hurricane |
| style="text-align:left" | NA Hurricane |
||
| style="text-align:right" | 1.2 |
| style="text-align:right" | 1.2 |
||
| style="text-align:right" | |
| style="text-align:right" | 600m |
||
|- |
|- |
||
| style="text-align:left" | NA Earthquake |
| style="text-align:left" | NA Earthquake |
||
| style="text-align:right" | 1.2 |
| style="text-align:right" | 1.2 |
||
| style="text-align:right" | |
| style="text-align:right" | 600m |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Other perils |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| style="text-align:right" | |
| style="text-align:right" | 400m |
||
|} |
|} |
||
</div> |
</div> |
||
* |
* Retention levels: Stable retention levels maintained in 2026 as in 2025. |
||
* NA Hurricane: varying retention between MX at EUR 400m and NA at EUR 600m. |
|||
* (diagram) '''Reinsurance segment''' protected via Alternative Capital & Cat Bonds <sup>p. 39</sup> |
|||
* |
* NA Earthquake: varying retention between MX at EUR 400m and NA at EUR 600m. |
||
* Other perils: includes Turkey earthquake, other Europe and NA perils, South America Earthquake, and other secondary perils. |
|||
* '''Europe Flood''': Capacity EUR 2.1bn, Retention EUR 450m <sup>p. 39</sup> |
|||
* Reinsurance segment: Alternative Capital & Cat Bonds utilized. |
|||
* '''Europe Earthquake''': Capacity EUR 2.1bn, Retention EUR 400m <sup>p. 39</sup> |
|||
* '''NA Hurricane''': Capacity EUR 1.2bn, Retention EUR 600m <sup>p. 39</sup> |
|||
* '''NA Earthquake''': Capacity EUR 1.2bn, Retention EUR 600m <sup>p. 39</sup> |
|||
* '''Per other perils''': Capacity [unlabeled bar], Retention EUR 400m <sup>p. 39</sup> |
|||
=== P&C | AXA Group earnings deviation with different levels of Nat Cat cost 1 in 2026 === |
=== P&C | AXA Group earnings deviation with different levels of Nat Cat cost 1 in 2026 === |
||
* '''Nat Cat definition''': Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance <sup>p. 40</sup>. |
|||
<div style="overflow-x:auto"> |
|||
* '''Deviation baseline''': Compared to a normalized level of costs expected in an average year, which is ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance <sup>p. 40</sup>. |
|||
{| class="wikitable fintable" |
|||
* (bar) '''Earnings deviation''': Group underlying earnings deviation to average Nat Cat charges in 2026 net of reinsurance, post-tax <sup>p. 40</sup>. |
|||
** '''More severe years''': Negative deviation in ca. 40% of cases; 1/20y (95th percentile) EUR -1.2bn, 1/10y (90th percentile) EUR -0.8bn, 1/5y (80th percentile) EUR -0.4bn <sup>p. 40</sup>. |
|||
! style="text-align:left" | EUR billion |
|||
** '''Median''': 50th percentile at EUR +0.1bn <sup>p. 40</sup>. |
|||
! class="col-s" style="text-align:right" | Earnings deviation |
|||
** '''Less severe years''': Positive deviation in ca. 60% of cases; 1/5y (20th percentile) EUR +0.5bn, 1/10y (10th percentile) EUR +0.7bn, 1/20y (5th percentile) EUR +0.8bn <sup>p. 40</sup>. |
|||
|- |
|||
* (bar) '''Expected Nat Cat''': Average expected Nat Cat charges net of reinsurance, pre-tax <sup>p. 40</sup>. |
|||
| style="text-align:left" | 1/20y (95th percentile) |
|||
** '''FY25''': EUR 2.6bn (Estimated impact on GEP: ca. 4.5%) <sup>p. 40</sup>. |
|||
| style="text-align:right" | -1.2 |
|||
** '''FY26''': EUR 2.7bn (Estimated impact on GEP: ca. 4.5%) <sup>p. 40</sup>. |
|||
|- |
|||
| style="text-align:left" | 1/10y (90th percentile) |
|||
| style="text-align:right" | -0.8 |
|||
|- |
|||
| style="text-align:left" | 1/5y (80th percentile) |
|||
| style="text-align:right" | -0.4 |
|||
|- |
|||
| style="text-align:left" | Median (50th percentile) |
|||
| style="text-align:right" | 0.1 |
|||
|- |
|||
| style="text-align:left" | 1/5y (20th percentile) |
|||
| style="text-align:right" | 0.5 |
|||
|- |
|||
| style="text-align:left" | 1/10y (10th percentile) |
|||
| style="text-align:right" | 0.7 |
|||
|- |
|||
| style="text-align:left" | 1/20y (5th percentile) |
|||
| style="text-align:right" | 0.8 |
|||
|} |
|||
</div> |
|||
* '''Table of contents''' <sup>p. 41</sup>: |
|||
<div style="overflow-x:auto"> |
|||
** 1. Debt and Invested Assets <sup>p. 31</sup> |
|||
{| class="wikitable fintable" |
|||
** 2. Additional P&C disclosures <sup>p. 36</sup> |
|||
** 3. '''Additional IFRS17 disclosures''' <sup>p. 41</sup> |
|||
! style="text-align:left" | EUR billion |
|||
** 4. Sustainability <sup>p. 44</sup> |
|||
! class="col-s" style="text-align:right" | 2025 |
|||
! class="col-s" style="text-align:right" | 2026 |
|||
|- |
|||
| style="text-align:left" | Expected Nat Cat charges |
|||
| style="text-align:right" | 2.6 |
|||
| style="text-align:right" | 2.7 |
|||
|} |
|||
</div> |
|||
* '''More severe years''' (Negative deviation in ca. 40% of cases) |
|||
* '''Less severe years''' (Positive deviation in ca. 60% of cases) |
|||
* '''2025''': Estimated impact on GEP: ca. 4.5% |
|||
* '''2026''': Estimated impact on GEP: ca. 4.5% |
|||
* '''Additional IFRS17 disclosures''' is the active section (p.41) <sup>p. 41</sup> |
|||
* Other sections listed: |
|||
** '''Debt and Invested Assets''' (p.31) <sup>p. 41</sup> |
|||
** '''Additional P&C disclosures''' (p.36) <sup>p. 41</sup> |
|||
** '''Sustainability''' (p.44) <sup>p. 41</sup> |
|||
=== P&C | Margin analysis === |
=== P&C | Margin analysis === |
||
| Line 1,353: | Line 1,388: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ P&C |
|+ P&C margin analysis, FY25 vs FY24 at constant FX <sup>p. 42</sup> |
||
! style="text-align:left" | EUR million unless otherwise mentioned |
! style="text-align:left" | EUR million unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change vs FY24 |
||
! class="col-m" style="text-align:right" | Other metrics |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Current Accident Year Undiscounted Technical Margin |
||
| style="text-align:right" | 8,040 |
|||
| style="text-align:right" | +681 |
|||
|- |
|||
| style="text-align:left" | Tax |
|||
| style="text-align:right" | -2,060 |
|||
| style="text-align:right" | -169 |
|||
|- |
|||
| style="text-align:left" | Affiliates, Minority interests & Other |
|||
| style="text-align:right" | -108 |
|||
| style="text-align:right" | -10 |
|||
|- |
|||
| style="text-align:left" | Underlying earnings |
|||
| style="text-align:right" | 5,872 |
|||
| style="text-align:right" | +501 |
|||
|} |
|||
</div> |
|||
* Underlying earnings up 9% at constant FX |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
! style="text-align:left" | EUR million unless otherwise mentioned |
|||
! class="col-s" style="text-align:right" | Technical result (pre-tax) |
|||
|- |
|||
| style="text-align:left" | Current accident year undiscounted technical margin |
|||
| style="text-align:right" | 2,778 |
| style="text-align:right" | 2,778 |
||
| style="text-align:right" | +707 |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Gross |
| style="text-align:left" | Gross Earned Premiums |
||
| style="text-align:right" | 57,656 |
| style="text-align:right" | 57,656 |
||
| style="text-align:right" | +6% |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Current |
| style="text-align:left" | Current Accident Year Undiscounted Combined Ratio |
||
| style="text-align:right" | 95.2% |
| style="text-align:right" | 95.2% |
||
| style="text-align:right" | -1.0pt |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Nat Cats |
| style="text-align:left" | Nat Cats |
||
| style="text-align:right" | 3.4% |
| style="text-align:right" | 3.4% |
||
| style="text-align:right" | -0.4pt |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Current |
| style="text-align:left" | Current Accident Year Discounting |
||
| style="text-align:right" | 2,009 |
| style="text-align:right" | 2,009 |
||
| style="text-align:right" | +115 |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Discounting |
| style="text-align:left" | Discounting Ratio (in Combined Ratio points) |
||
| style="text-align:right" | -3.5% |
| style="text-align:right" | -3.5% |
||
| style="text-align:right" | +0.0pt |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Current |
| style="text-align:left" | Current Accident Year Net Claims reserves |
||
| style="text-align:right" | 19.0bn |
| style="text-align:right" | 19.0bn |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Duration |
| style="text-align:left" | Duration |
||
| style="text-align:right" | 4.0 years |
| style="text-align:right" | 4.0 years |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Current |
| style="text-align:left" | Current Accident Year Discount rate |
||
| style="text-align:right" | 2.8% |
| style="text-align:right" | 2.8% |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Prior |
| style="text-align:left" | Prior Years' Reserve Development (PYD) |
||
| style="text-align:right" | 622 |
| style="text-align:right" | 622 |
||
| style="text-align:right" | -341 |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | PYD ratio |
| style="text-align:left" | PYD ratio |
||
| style="text-align:right" | -1.1% |
| style="text-align:right" | -1.1% |
||
| style="text-align:right" | +0.7pt |
|||
|} |
|||
| style="text-align:right" | — |
|||
</div> |
|||
* Gross earned premiums up 6% |
|||
* Current accident year undiscounted combined ratio down 1.0pt |
|||
* Nat Cats down 0.4pt |
|||
* Current accident year discounting up EUR 115m |
|||
* Discounting ratio up 0.0pt |
|||
* Prior years' reserve development (PYD) down EUR 341m |
|||
* PYD ratio up 0.7pt |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
! style="text-align:left" | EUR million unless otherwise mentioned |
|||
! class="col-s" style="text-align:right" | Financial result (pre-tax) |
|||
|- |
|- |
||
| style="text-align:left" | Investment |
| style="text-align:left" | Investment Income |
||
| style="text-align:right" | 3,988 |
| style="text-align:right" | 3,988 |
||
| style="text-align:right" | +435 |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Average |
| style="text-align:left" | FY25 Average Assets |
||
| style="text-align:right" | 115bn |
| style="text-align:right" | 115bn |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Asset book yield |
| style="text-align:left" | Asset book yield |
||
| style="text-align:right" | 3.5% |
| style="text-align:right" | 3.5% |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Reinvestment yield |
| style="text-align:left" | FY25 Reinvestment yield (on fixed income assets) |
||
| style="text-align:right" | 4.3% |
| style="text-align:right" | 4.3% |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Insurance |
| style="text-align:left" | Insurance Finance Expenses |
||
| style="text-align:right" | -1,358 |
| style="text-align:right" | -1,358 |
||
| style="text-align:right" | -235 |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Reserves at locked-in rate |
| style="text-align:left" | FY24 Reserves at locked-in rate |
||
| style="text-align:right" | 71bn |
| style="text-align:right" | 71bn |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Liability book yield |
| style="text-align:left" | Liability book yield |
||
| style="text-align:right" | 1.9% |
| style="text-align:right" | 1.9% |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Underlying Earnings before tax |
|||
| style="text-align:right" | 8,040 |
|||
| style="text-align:right" | +681 |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Tax |
|||
| style="text-align:right" | -2,060 |
|||
| style="text-align:right" | -169 |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Affiliates, Minority interests & Other |
|||
| style="text-align:right" | -108 |
|||
| style="text-align:right" | -10 |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Underlying Earnings |
|||
| style="text-align:right" | 5,872 |
|||
| style="text-align:right" | +501 |
|||
| style="text-align:right" | growth vs. FY24 at constant FX of +9% |
|||
|} |
|} |
||
</div> |
</div> |
||
* Investment income up EUR 435m |
|||
* Insurance finance expenses down EUR 235m |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ FY25 sensitivity to Current Accident Year discount rate changes <sup>p. 42</sup> |
|||
! |
! style="text-align:left" | Change in discount rate |
||
! class="col-s" style="text-align:right" | Impact (EUR billion) |
|||
|- |
|- |
||
| style="text-align:left" | +25bps |
| style="text-align:left" | +25bps |
||
| Line 1,472: | Line 1,522: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" |
{| class="wikitable" |
||
|+ 2026e Insurance Finance Expenses (pre-tax) and sensitivity <sup>p. 42</sup> |
|||
! style="text-align:left" | Item |
|||
! class="col-s" style="text-align:right" | Value |
! class="col-s" style="text-align:right" | Value |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | 2026e Insurance Finance Expenses (pre-tax) |
||
| class="col-s" style="text-align:right" | ~ - |
| class="col-s" style="text-align:right" | ~ -1.4bn |
||
|- |
|- |
||
| style="text-align:left" | Sensitivity to |
| style="text-align:left" | Sensitivity to 2025 current AY Discount +25bps |
||
| class="col-s" style="text-align:right" | ~ - |
| class="col-s" style="text-align:right" | ~ -50m |
||
|- |
|- |
||
| style="text-align:left" | Sensitivity to |
| style="text-align:left" | Sensitivity to 2025 current AY Discount -25bps |
||
| class="col-s" style="text-align:right" | ~ + |
| class="col-s" style="text-align:right" | ~ +50m |
||
|} |
|} |
||
</div> |
</div> |
||
* '''Current accident year undiscounted technical margin''': EUR 2,778m (+EUR 707m) <sup>p. 42</sup> |
|||
=== L&H | Margin analysis === |
=== L&H | Margin analysis === |
||
| Line 1,491: | Line 1,541: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ L&H margin analysis, FY25 vs FY24 at constant FX <sup>p. 43</sup> |
||
! style="text-align:left" | EUR million unless otherwise mentioned |
! style="text-align:left" | EUR million unless otherwise mentioned |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change vs FY24 |
||
! class="col-m" style="text-align:right" | Other metrics |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Short-term Technical Margin |
||
| style="text-align:right" | 4,229 |
|||
| style="text-align:right" | +205 |
|||
|- |
|||
| style="text-align:left" | Tax |
|||
| style="text-align:right" | -800 |
|||
| style="text-align:right" | +65 |
|||
|- |
|||
| style="text-align:left" | Affiliates, Minority interests & Other |
|||
| style="text-align:right" | 72 |
|||
| style="text-align:right" | -51 |
|||
|- |
|||
| style="text-align:left" | Underlying earnings |
|||
| style="text-align:right" | 3,501 |
|||
| style="text-align:right" | +219 |
|||
|} |
|||
</div> |
|||
* Underlying earnings up 7% at constant FX |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
! style="text-align:left" | EUR million unless otherwise mentioned |
|||
! class="col-s" style="text-align:right" | Technical result (pre-tax) |
|||
|- |
|||
| style="text-align:left" | Short-term technical margin |
|||
| style="text-align:right" | 479 |
| style="text-align:right" | 479 |
||
| style="text-align:right" | +60 |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Gross |
| style="text-align:left" | Gross Earned Premiums |
||
| style="text-align:right" | 17,416 |
| style="text-align:right" | 17,416 |
||
| style="text-align:right" | +10% |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | All |
| style="text-align:left" | All Year Combined Ratio |
||
| style="text-align:right" | 97.2% |
| style="text-align:right" | 97.2% |
||
| style="text-align:right" | -0.1pt |
|||
| style="text-align:right" | includes recapture of Laya |
|||
|- |
|- |
||
| style="text-align:left" | Long-term |
| style="text-align:left" | Long-term Technical Margin |
||
| style="text-align:right" | 2,804 |
| style="text-align:right" | 2,804 |
||
| style="text-align:right" | +156 |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | CSM release |
| style="text-align:left" | CSM release |
||
| style="text-align:right" | 2,954 |
| style="text-align:right" | 2,954 |
||
| style="text-align:right" | +215 |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Technical experience |
| style="text-align:left" | Technical experience |
||
| style="text-align:right" | -150 |
| style="text-align:right" | -150 |
||
| style="text-align:right" | -58 |
|||
|} |
|||
| style="text-align:right" | — |
|||
</div> |
|||
* Short-term technical margin up EUR 60m, includes recapture of Laya |
|||
* Gross earned premiums up 10% |
|||
* All year combined ratio down 0.1pt |
|||
* Long-term technical margin up EUR 156m |
|||
* CSM release up EUR 215m |
|||
* Technical experience down EUR 58m |
|||
<div style="overflow-x:auto"> |
|||
{| class="wikitable fintable" |
|||
! style="text-align:left" | EUR million unless otherwise mentioned |
|||
! class="col-s" style="text-align:right" | Financial result (pre-tax) |
|||
|- |
|- |
||
| style="text-align:left" | Investment |
| style="text-align:left" | Investment Income (non-VFA only) |
||
| style="text-align:right" | 2,484 |
| style="text-align:right" | 2,484 |
||
| style="text-align:right" | -1 |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Average |
| style="text-align:left" | FY25 Average Assets |
||
| style="text-align:right" | 98bn |
| style="text-align:right" | 98bn |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Asset book yield |
| style="text-align:left" | Asset book yield |
||
| style="text-align:right" | 2.5% |
| style="text-align:right" | 2.5% |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Reinvestment yield |
| style="text-align:left" | FY25 Reinvestment yield (on fixed income assets) |
||
| style="text-align:right" | 3.8% |
| style="text-align:right" | 3.8% |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Insurance |
| style="text-align:left" | Insurance Finance Expenses (non-VFA only) |
||
| style="text-align:right" | -1,538 |
| style="text-align:right" | -1,538 |
||
| style="text-align:right" | -9 |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Reserves at locked-in rate |
| style="text-align:left" | FY24 Reserves at locked-in rate |
||
| style="text-align:right" | 62bn |
| style="text-align:right" | 62bn |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|- |
||
| style="text-align:left" | Liability book yield |
| style="text-align:left" | Liability book yield |
||
| style="text-align:right" | 2.5% |
| style="text-align:right" | 2.5% |
||
| style="text-align:right" | — |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Underlying Earnings before tax |
|||
| style="text-align:right" | 4,229 |
|||
| style="text-align:right" | +205 |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Tax |
|||
| style="text-align:right" | -800 |
|||
| style="text-align:right" | +65 |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Affiliates, Minority interests & Other |
|||
| style="text-align:right" | 72 |
|||
| style="text-align:right" | -51 |
|||
| style="text-align:right" | — |
|||
|- |
|||
| style="text-align:left" | Underlying Earnings |
|||
| style="text-align:right" | 3,501 |
|||
| style="text-align:right" | +219 |
|||
| style="text-align:right" | growth vs. FY24 at constant FX of +7% |
|||
|} |
|} |
||
</div> |
</div> |
||
* Investment income (non-VFA only) down EUR 1m |
|||
* Insurance finance expenses (non-VFA only) down EUR 9m |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Life & Health FY25 CSM |
|+ Life & Health FY25 CSM Key Sensitivities <sup>p. 43</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | Scenario |
||
! class="col-s" style="text-align:right" | EUR billion |
! class="col-s" style="text-align:right" | EUR billion |
||
|- |
|- |
||
| Line 1,614: | Line 1,669: | ||
</div> |
</div> |
||
* ''' |
* '''Table of contents''' <sup>p. 44</sup>: |
||
** 1. Debt and Invested Assets <sup>p. 31</sup> |
|||
* Other sections listed: |
|||
** |
** 2. Additional P&C disclosures <sup>p. 36</sup> |
||
** |
** 3. Additional IFRS17 disclosures <sup>p. 41</sup> |
||
** ''' |
** 4. '''Sustainability''' <sup>p. 44</sup> |
||
=== Expanding AXA's role in society: AXA for Progress Index 1 === |
=== Expanding AXA's role in society: AXA for Progress Index 1 === |
||
| Line 1,637: | Line 1,692: | ||
| class="col-m" style="text-align:right" | EUR 1.4bn |
| class="col-m" style="text-align:right" | EUR 1.4bn |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | P&C GWP to support transition underwriting (cumulative 2024-2026) |
||
| class="col-m" style="text-align:right" | EUR 6bn |
| class="col-m" style="text-align:right" | EUR 6bn |
||
| class="col-m" style="text-align:right" | EUR 4.6bn |
| class="col-m" style="text-align:right" | EUR 4.6bn |
||
|- |
|- |
||
| style="text-align:left" | Climate adaptation solutions & services |
| style="text-align:left" | Climate adaptation solutions & services (cumulative 2024-2026) |
||
| class="col-m" style="text-align:right" | >20,000 |
| class="col-m" style="text-align:right" | >20,000 |
||
| class="col-m" style="text-align:right" | 19,698 |
| class="col-m" style="text-align:right" | 19,698 cumulative 2024-2025 |
||
|- |
|- |
||
| style="text-align:left" | Inclusive insurance customers |
| style="text-align:left" | Inclusive insurance customers |
||
| Line 1,649: | Line 1,704: | ||
| class="col-m" style="text-align:right" | 20.6m |
| class="col-m" style="text-align:right" | 20.6m |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | AXA Group employees trained on climate adaptation |
||
| class="col-m" style="text-align:right" | >80,000 by 2026 |
| class="col-m" style="text-align:right" | >80,000 by 2026 |
||
| class="col-m" style="text-align:right" | 46,420 |
| class="col-m" style="text-align:right" | 46,420 |
||
|- |
|- |
||
| style="text-align:left" | Absolute carbon emissions reduction |
| style="text-align:left" | Absolute carbon emissions reduction |
||
| class="col-m" style="text-align:right" | -50% by 2030 |
| class="col-m" style="text-align:right" | -50% by 2030 |
||
| class="col-m" style="text-align:right" | -64% reduction against 2019 |
| class="col-m" style="text-align:right" | -64% reduction against 2019 |
||
|- |
|- |
||
| style="text-align:left" | Employee volunteering engagement |
| style="text-align:left" | Employee volunteering engagement |
||
| class="col-m" style="text-align:right" | 50% by 2026 |
| class="col-m" style="text-align:right" | 50% of AXA Group employees engaged in volunteering activities by 2026 |
||
| class="col-m" style="text-align:right" | 56% |
| class="col-m" style="text-align:right" | 56% |
||
|} |
|} |
||
</div> |
</div> |
||
* '''Climate adaptation solutions & services''' target (cumulative 2024-2026): >20,000 (target revised in 2025 from >9,000); 2025 Result: 19,698 cumulative 2024-2025 <sup>p. 45</sup> |
|||
* '''Absolute carbon emissions reduction''' target: -50% by 2030 (against 2019 baseline; scope: energy Scopes 1 and 2, car fleet and business travel) and offset of residual emissions; 2025 Result: -64% reduction against 2019 <sup>p. 45</sup> |
|||
=== Sustainability Performance & Ratings === |
=== Sustainability Performance & Ratings === |
||
| Line 1,667: | Line 1,724: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable" |
{| class="wikitable" |
||
|+ ESG ratings and scores |
|+ ESG ratings and scores <sup>p. 46</sup> |
||
! style="text-align:left" | |
! style="text-align:left" | Provider |
||
! class="col-m" style="text-align:right" | 2025 Score |
! class="col-m" style="text-align:right" | 2025 Score / Rating |
||
|- |
|- |
||
| style="text-align:left" | S&P Global |
| style="text-align:left" | S&P Global |
||
| class="col-m" style="text-align:right" | 97th percentile |
| class="col-m" style="text-align:right" | 97th percentile¹ in Dow Jones Best-in-Class Europe & World indices |
||
|- |
|- |
||
| style="text-align:left" | MSCI |
| style="text-align:left" | MSCI |
||
| Line 1,684: | Line 1,741: | ||
|- |
|- |
||
| style="text-align:left" | FTSE Russell |
| style="text-align:left" | FTSE Russell |
||
| class="col-m" style="text-align:right" | 4.3/5 |
| class="col-m" style="text-align:right" | 4.3/5 in FTSE4Good Index Series |
||
|} |
|} |
||
</div> |
</div> |
||
* The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives |
* "The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (more precisely AXA Restricted Shares). Results as of February 6th, 2026." |
||
* '''FTSE Russell''': 2025 score 4.3/5 in FTSE4Good Index Series <sup>p. 46</sup> |
|||
=== Scope === |
=== Scope === |
||
| Line 1,695: | Line 1,751: | ||
* '''Europe''': includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holdings), Italy (insurance activities), Prima (insurance activities) and AXA Life Europe (insurance activities) <sup>p. 47</sup> |
* '''Europe''': includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holdings), Italy (insurance activities), Prima (insurance activities) and AXA Life Europe (insurance activities) <sup>p. 47</sup> |
||
* '''AXA XL''': includes insurance and reinsurance activities and holding <sup>p. 47</sup> |
* '''AXA XL''': includes insurance and reinsurance activities and holding <sup>p. 47</sup> |
||
* '''Asia, Africa & EME-LATAM''': <sup>p. 47</sup> |
* '''Asia, Africa & EME-LATAM''': includes: <sup>p. 47</sup> |
||
** '''Asia''': Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, China P&C, South Korea, and Asia Holdings which are fully consolidated |
** '''Asia''': Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, China P&C, South Korea, and Asia Holdings which are fully consolidated, and China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S and India (Life activities disposed on March 11, 2024 and holding) businesses which are consolidated under the equity method and contribute only to NBV, PVEP, the underlying earnings and net income <sup>p. 47</sup> |
||
** '''Africa''': Morocco (insurance activities and holding) |
** '''Africa''': Morocco (insurance activities and holding) and Nigeria (insurance activities and holding), Egypt (insurance activities and holding) which are fully consolidated <sup>p. 47</sup> |
||
** '''EME-LATAM''': Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding) and Türkiye (insurance activities and holding) which are fully consolidated |
** '''EME-LATAM''': Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding) and Türkiye (insurance activities and holding) which are fully consolidated as well as Russia (Reso) (insurance activities) which consolidated under the equity method and contributes only to the net income <sup>p. 47</sup> |
||
** '''AXA Mediterranean Holdings''' |
** '''AXA Mediterranean Holdings''' <sup>p. 47</sup> |
||
* '''Transversal & Other''': includes AXA Assistance, AXA Liabilities Managers, AXA and other Central Holdings <sup>p. 47</sup> |
* '''Transversal & Other''': includes AXA Assistance, AXA Liabilities Managers, AXA and other Central Holdings <sup>p. 47</sup> |
||
* '''AXA Investment Managers''' (until July 1, 2025): includes AXA Investment Managers, Select (previously referred to as Architas) and Capza which are fully consolidated and Asian joint ventures which are consolidated under the equity method <sup>p. 47</sup> |
* '''AXA Investment Managers''' (until July 1, 2025): includes AXA Investment Managers, Select (previously referred to as Architas) and Capza which are fully consolidated and Asian joint ventures which are consolidated under the equity method <sup>p. 47</sup> |
||
* '''Accounting standards''': |
* '''Accounting standards''': Unless otherwise specified herein, all comparative figures going back to 2023 are under the IFRS17/9 accounting standards that became effective on January 1, 2023; figures for financial periods prior to 2023 have not been restated under IFRS17/9 and are presented under IFRS4 <sup>p. 47</sup> |
||
=== Glossary === |
=== Glossary === |
||
* '''Capital-light G/A products''': encompass all products with no guarantees, with guarantees at maturity only or with guarantees equal to or lower than 0% <sup>p. 48</sup> |
* '''Capital-light G/A products''': encompass all products with no guarantees, with guarantees at maturity only or with guarantees equal to or lower than 0% <sup>p. 48</sup> |
||
* '''Contractual Service Margin''': a component of the carrying amount of asset or liability for a group of insurance contracts representing the unearned profit to be recognized as services are provided to policyholders <sup>p. 48</sup> |
* '''Contractual Service Margin''' (CSM): a component of the carrying amount of asset or liability for a group of insurance contracts representing the unearned profit to be recognized as services are provided to policyholders <sup>p. 48</sup> |
||
* '''CSM release''': a portion of CSM stock net of reinsurance at the end of the defined period flowing through profit and loss representing the estimated profit earned by the insurer for providing insurance services during the reporting period <sup>p. 48</sup> |
* '''CSM release''': a portion of CSM stock net of reinsurance at the end of the defined period flowing through profit and loss representing the estimated profit earned by the insurer for providing insurance services during the reporting period <sup>p. 48</sup> |
||
* '''Economic variance''': corresponds to the variance of the year-end CSM arising from changes in market conditions, net of the underlying return on in-force <sup>p. 48</sup> |
* '''Economic variance''': corresponds to the variance of the year-end CSM arising from changes in market conditions, net of the underlying return on in-force <sup>p. 48</sup> |
||
* '''Financial result''': consists of investment income on assets backing BBA and PAA contracts as well as assets backing shareholder's equity, net of the insurance finance expenses (IFE) defined as the unwind of the present value of future cash flow <sup>p. 48</sup> |
* '''Financial result''': consists of investment income on assets backing BBA and PAA contracts as well as assets backing shareholder's equity, net of the insurance finance expenses (IFE) defined as the unwind of the present value of future cash flow <sup>p. 48</sup> |
||
* '''Gross Written Premiums''' and Other Revenues: represent the insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business); Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities) <sup>p. 48</sup> |
* '''Gross Written Premiums''' and Other Revenues (GWP & Other Revenues): represent the insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business); Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities) <sup>p. 48</sup> |
||
* '''New Business Value''': the value of newly issued contracts during the current year |
* '''New Business Value''' (NBV): the value of newly issued contracts during the current year, consisting of the sum of (i) the new business contractual service margin, (ii) the present value of the future profits of short-term newly issued contracts during the period, carried by Life entities, considering expected renewals, (iii) the present value of the future profits of pure investment contracts accounted for under IFRS 9, net of (iv) the cost of reinsurance, (v) taxes and (vi) minority interests <sup>p. 48</sup> |
||
* '''New Business CSM''': a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided <sup>p. 48</sup> |
* '''New Business CSM''' (NB CSM): a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided <sup>p. 48</sup> |
||
* '''New Business Value margin''': ratio of (i) NBV, representing the value of newly issued contracts during the current year, to (ii) PVEP <sup>p. 48</sup> |
* '''New Business Value margin''' (NBV margin): ratio of (i) NBV, representing the value of newly issued contracts during the current year, to (ii) PVEP <sup>p. 48</sup> |
||
* '''Operating variance''': the variation of the year-end CSM versus the expected at opening due to (i) the differences between realized and expected operational assumptions, (ii) changes in assumptions such as mortality, longevity, lapses and expenses, and (iii) impact of model changes; net of reinsurance <sup>p. 48</sup> |
* '''Operating variance''': the variation of the year-end CSM versus the expected at opening due to (i) the differences between realized and expected operational assumptions, (ii) changes in assumptions such as mortality, longevity, lapses and expenses, and (iii) impact of model changes; operating variance is net of reinsurance <sup>p. 48</sup> |
||
* '''Present value of expected premiums''': the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term; discounted at the reference interest rate and Group share <sup>p. 48</sup> |
* '''Present value of expected premiums''' (PVEP): the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term; PVEP is discounted at the reference interest rate and PVEP is Group share <sup>p. 48</sup> |
||
* '''Technical experience''': consists of the impacts on the underlying earnings of (i) the difference between the expected and incurred cash-flows of the defined period, (ii) the risk adjustment release, (iii) the changes in onerous contracts, and (iv) the other long-term elements which are mainly composed of non-attributable expenses <sup>p. 48</sup> |
* '''Technical experience''': consists of the impacts on the underlying earnings of (i) the difference between the expected and incurred cash-flows of the defined period, (ii) the risk adjustment release, (iii) the changes in onerous contracts, and (iv) the other long-term elements which are mainly composed of non-attributable expenses <sup>p. 48</sup> |
||
* '''Underlying return on in-force''': represents the release of Time Value of Options & Guarantees (TVOG) plus the unwind of CSM at the reference rate plus the underlying financial over-performance <sup>p. 48</sup> |
* '''Underlying return on in-force''': represents the release of Time Value of Options & Guarantees (TVOG) plus the unwind of CSM at the reference rate plus the underlying financial over-performance <sup>p. 48</sup> |
||
| Line 1,722: | Line 1,778: | ||
=== February 26, 2026 Thank you Full Year 2025 earnings === |
=== February 26, 2026 Thank you Full Year 2025 earnings === |
||
* |
* '''Presentation conclusion''': Full Year 2025 Earnings presentation concluded on February 26, 2026 <sup>p. 49</sup> |
||
== Abbreviations == |
== Abbreviations == |
||
* '''AA''': |
* '''AA''': Senior bond rating (Standard & Poor's) |
||
* '''AAA''': |
* '''AAA''': Senior bond rating (Standard & Poor's) |
||
* '''ABS''': Asset-Backed Securities |
* '''ABS''': Asset-Backed Securities |
||
* '''AEP''': Aggregate Exceedance Probability |
|||
* '''AI''': Artificial Intelligence |
* '''AI''': Artificial Intelligence |
||
* '''APAC''': Asia-Pacific |
* '''APAC''': Asia-Pacific |
||
* '''AXA IM''': AXA Investment Managers |
* '''AXA IM''': AXA Investment Managers |
||
* '''AXA XL''': AXA XL (AXA's large property and casualty commercial lines and specialty risk division) |
|||
* '''AY''': Accident Year |
* '''AY''': Accident Year |
||
* '''BBA''': Beneficial interest in a Block of business of Annuities |
|||
* '''BBA''': Benefit-Bearing Assets |
|||
* '''CDP''': Carbon Disclosure Project |
* '''CDP''': Carbon Disclosure Project |
||
* '''CLO''': Collateralized Loan Obligation |
* '''CLO''': Collateralized Loan Obligation |
||
| Line 1,739: | Line 1,797: | ||
* '''CSA''': Corporate Sustainability Assessment |
* '''CSA''': Corporate Sustainability Assessment |
||
* '''CSM''': Contractual Service Margin |
* '''CSM''': Contractual Service Margin |
||
* '''CY''': |
* '''CY''': Calendar Year |
||
* '''DPS''': Dividend Per Share |
* '''DPS''': Dividend Per Share |
||
* '''EME''': Emerging Markets |
* '''EME''': Emerging Markets |
||
* '''EOF''': Eligible Own Funds |
|||
* '''EPS''': Earnings Per Share |
* '''EPS''': Earnings Per Share |
||
* '''ESG''': Environmental, Social, and Governance |
* '''ESG''': Environmental, Social, and Governance |
||
| Line 1,749: | Line 1,808: | ||
* '''GAAP''': Generally Accepted Accounting Principles |
* '''GAAP''': Generally Accepted Accounting Principles |
||
* '''GEP''': Gross Earned Premiums |
* '''GEP''': Gross Earned Premiums |
||
* '''GF EUR''': Grandfathered Euro |
|||
* '''GF GBP''': Grandfathered Great British Pound |
|||
* '''GWP''': Gross Written Premiums |
* '''GWP''': Gross Written Premiums |
||
* '''HKD''': Hong Kong Dollar |
* '''HKD''': Hong Kong Dollar |
||
| Line 1,760: | Line 1,821: | ||
* '''LTV''': Loan-to-Value |
* '''LTV''': Loan-to-Value |
||
* '''MSCI''': Morgan Stanley Capital International |
* '''MSCI''': Morgan Stanley Capital International |
||
* '''MX''': Mexico |
|||
* '''NA''': North America |
* '''NA''': North America |
||
* '''NB CSM''': New Business Contractual Service Margin |
* '''NB CSM''': New Business Contractual Service Margin |
||
* '''NBV''': New Business Value |
* '''NBV''': New Business Value |
||
* '''NHG''': Nationale Hypotheek Garantie |
* '''NHG''': Nationale Hypotheek Garantie (National Mortgage Guarantee) |
||
* '''NPS''': Net Promoter Score |
* '''NPS''': Net Promoter Score |
||
* '''OCI''': Other Comprehensive Income |
* '''OCI''': Other Comprehensive Income |
||
| Line 1,771: | Line 1,833: | ||
* '''PYD''': Prior Years' Reserve Development |
* '''PYD''': Prior Years' Reserve Development |
||
* '''ROE''': Return On Equity |
* '''ROE''': Return On Equity |
||
* '''SCR''': Solvency Capital Requirement |
|||
* '''SHE''': Shareholders' Equity |
* '''SHE''': Shareholders' Equity |
||
* '''SME''': Small and Medium-sized Enterprises |
* '''SME''': Small and Medium-sized Enterprises |
||
Revision as of 23:59, 21 June 2026
| Document info | |
|---|---|
| Organization | AXA |
| Year | 2025 |
| Period | FY |
| Period label | FY25 |
| Document type | Analyst presentation |
| Publication date | 2026-02-26 |
| Language | English |
| Pages | 49 |
| Source | Original URL |
| Archive file | .md file |
This article summarizes AXA's full-year 2025 earnings presentation, published on 26 February 2026.
Front matter
Full Year 2025 earnings presentation
- Presentation date February 26, 2026 p. 1
- Company AXA p. 1
Important legal information and cautionary statements concerning forward-looking statements and the use of non-GAAP financial measures
- Forward-looking statements include predictions of future events, trends, plans, expectations, or objectives p. 2.
- Underlying EPS (UEPS) growth guidance for 2026 is provided as one-off guidance in the context of the last year of the Group's current strategic plan p. 2.
- Risk factors are described in Part 5 of AXA's Universal Registration Document for the year ended December 31, 2024 p. 2.
- Alternative performance measures (APMs) used by management include underlying earnings, UEPS, underlying return on equity, combined ratio, and debt gearing p. 2.
- Financial statements for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of audit procedures p. 2.
Table of contents
- FY25 Highlights presented by Thomas Buberl, Group CEO p. 3
- FY25 Business Performance presented by Guillaume Borie, Global Head of Finance, Strategy, Underwriting, Risk, and Technology p. 3
- FY25 Financial Performance presented by Alban de Mailly Nesle, Group CFO p. 3
FY25 Highlights
- Session presenter Thomas Buberl, Group CEO p. 4
Full Year 2025 | Excellent performance
| Metric | Value |
|---|---|
| Revenues | +6% vs. FY24 |
| Underlying EPS | +8% vs. FY24 |
| Return on equity (ROE) | 16% |
| Solvency II ratio | 224% |
| Shareholder value | +8% DPS growth and EUR 1.25bn annual share buyback |
| Earnings guidance | Confident to deliver underlying EPS growth at the upper end of 6%-8% target range for 2026 |
- Dividend proposed by AXA's Board of Directors on February 25, 2026, subject to approval by the Shareholders' Annual General Meeting on April 30, 2026.
- Share buyback approved by AXA's Board of Directors on February 25, 2026, expected to commence as soon as reasonably practicable.
Executing the plan on growth, margin and efficiency
| EUR billion unless otherwise mentioned | FY24 | FY25 | Change (LFL) | Change (excluding AXA IM) |
|---|---|---|---|---|
| Underlying earnings | 8.1 | 8.4 | +6% | +9% |
- Top line growth +6% LFL, well balanced across lines: P&C +5%, Life +9%, Health +5%.
- Record profitability driven by further margin expansion in P&C and L&H, alongside improvement in efficiency.
- Scaling the business through continued investments in growth and technology.
- Earnings growth delivered consistently while enhancing reserve prudence.
Diversified franchise, well positioned in an attractive industry
| Segment | Share |
|---|---|
| Life | 33% |
| Health | 17% |
| Large & Specialty | 17% |
| SME & Mid-market | 16% |
| Retail | 17% |
- Secular trends fueling demand across businesses:
- Protection gaps and emerging corporate risks driving SME & Mid-market and Large & Specialty p. 7
- Demographics driving demand for private retirement and healthcare driving Life and Health p. 7
- Our right to win supported by four strategic pillars:
- Leading brand & high customer NPS p. 7
- Strong and diversified distribution p. 7
- Technical expertise to price & underwriting risks p. 7
- Scale offering cost advantage p. 7
Laying the foundation for the next plan
- Strategic pillars for the next plan:
- Clear tech and AI roadmap p. 8
- Driving efficiency p. 8
- Enhancing capital allocation discipline p. 8
- Building resilience p. 8
- Earnings growth sustainability supported by strong confidence p. 8
Section divider
- FY25 Business Performance presented by Guillaume Borie, Global Head of Finance, Strategy, Underwriting, Risk, and Technology p. 9
FY25 Business Performance
Strong delivery across our businesses
| EUR billion unless otherwise mentioned | % of total GWP | GWP | GWP change LFL | Underlying earnings | Underlying earnings change LFL |
|---|---|---|---|---|---|
| France | 27% | 31 | +6% | 2.2 | +7% |
| Europe | 38% | 43 | +6% | 3.5 | +9% |
| AXA XL | 17% | 19 | +4% | 1.9 | +9% |
| Asia, Africa & EME-LATAM | 18% | 20 | +13% | 1.5 | +6% |
P&C | Strong margins, confidence in sustaining growth
| EUR billion | GWP |
|---|---|
| Retail | — |
| SME & Mid-market | — |
| AXA XL (Large & Specialty) | — |
| Total | 58 |
- AXA XL includes AXA XL Re premiums of EUR 2.6bn p. 11
- Underlying earnings +9% LFL to EUR 5.9bn (reported change FY25 vs. FY24 at constant FX) p. 11
- Retail and SME & Mid-market strategic outlook:
- 2025: Growing volumes while expanding margins p. 11
- Beyond 2025: Investing to improve customer retention & expanding distribution footprint p. 11
- AXA XL (Large & Specialty) strategic outlook:
- 2025: Profitable growth with stable margins p. 11
- Beyond 2025: Capitalizing on attractive growth opportunities and continued cycle management p. 11
- Strategic enablers:
- Continued progress on efficiency p. 11
- Higher investment income p. 11
- Data & AI to further enhance customer experience & technical excellence p. 11
L&H | Good momentum, well positioned to capture growth opportunities
| EUR billion | GWP |
|---|---|
| Total | 57 |
| Long-term | — |
| Short-term | — |
- Underlying earnings +7% LFL to EUR 3.5bn (reported change FY25 vs. FY24 at constant FX) p. 12
- Long-term business strategic outlook:
- 2025: Accelerating net flows in Savings at attractive margins p. 12
- Beyond 2025: Capturing savings & retirement opportunity, sourcing best asset management products for our customers p. 12
- Short-term business strategic outlook:
- 2025: Growing technical results while absorbing Mexico VAT impact p. 12
- Beyond 2025: Capitalizing on demand for health & protection while further improving our margins p. 12
- Strategic enablers:
- Focus on cost reduction p. 12
- Increasing penetration of Protection riders in Savings offerings p. 12
- Leveraging AI to reduce claims leakage & improve customer outcomes in Health p. 12
FY25 Financial Performance
- Section divider slide presented by Alban de Mailly Nesle, Group CFO p. 13
P&C | Continued disciplined growth
| EUR billion unless otherwise mentioned | FY24 | FY25 | LFL Change | o/w pricing | o/w volume |
|---|---|---|---|---|---|
| Commercial lines | — | 35.8 | +4% | +2% | +2% |
| AXA XL Reinsurance | — | 2.6 | +8% | +0.3% | +7% |
| Retail lines | — | 19.7 | +7% | +5% | +2% |
| Total | 56.5 | 58.0 | +5% | — | — |
- Continued pricing momentum and volume growth in Mid-market and SME p. 14
- Growing in lines of business with attractive margins while remaining focused on retention at AXA XL Insurance p. 14
- Growth supported by alternative capital p. 14
- Favorable pricing trends and strong growth in net new contracts (+1.7m in FY25) p. 14
P&C | Delivering further margin expansion while enhancing reserve prudence
| % | FY24 | FY25 |
|---|---|---|
| Combined ratio | 91.0 | 90.6 |
| Undiscounted CY loss ratio (ex Nat Cat) | 67.4 | 67.0 |
| Expense ratio | 25.0 | 24.8 |
| Nat Cat | 3.8 | 3.4 |
| Prior year reserve development | -1.6 | -1.1 |
| Discount | -3.6 | -3.5 |
- Better undiscounted current year loss ratio excluding Nat Cat from margin expansion in Commercial lines SME & mid-market business and Personal lines reflecting favorable pricing environment p. 15
- Stable AXA XL Insurance margins at attractive levels reflecting disciplined cycle management p. 15
- Improvement in expense ratio reflecting the impact of efficiency measures, while continuing to invest in growth initiatives and technology p. 15
- Nat Cat charges below normalized load p. 15
- Lower reliance on prior year reserve development p. 15
- Taking advantage of a good year to enhance reserve prudence p. 15
P&C | Earnings growth from higher underwriting and financial result
| EUR million | Underlying earnings |
|---|---|
| FY24 | 5,510 |
| Volume growth | +292 |
| Margin improvement | +189 |
| Investment income | +435 |
| Insurance finance expenses | -235 |
| Tax | -169 |
| Affiliates, FX & other | -150 |
| FY25 | 5,872 |
- Underwriting result improved from strong volume growth and improved all-year combined ratio while enhancing reserve prudence p. 16.
- Investment income increased reflecting higher volumes and better reinvestment yields on fixed income assets p. 16.
- Unwind of discount of claims reserves was higher, in line with guidance p. 16.
- Forex impact was unfavorable notably due to USD depreciation vs. EUR p. 16.
- Underwriting result components include volume growth (+EUR 292m) and margin improvement (+EUR 189m) p. 16.
- Financial result components include investment income (+EUR 435m) and insurance finance expenses (-EUR 235m) p. 16.
- (waterfall) Underlying earnings bridge FY24→FY25: EUR 5,510m start → volume growth +EUR 292m → margin improvement +EUR 189m → investment income +EUR 435m → insurance finance expenses -EUR 235m → tax -EUR 169m → affiliates, FX & other -EUR 150m → EUR 5,872m end (+9% at constant FX) p. 16.
| EUR billion unless otherwise mentioned | FY24 | FY25 | LFL Change |
|---|---|---|---|
| Protection | — | 17.3 | +11% |
| Unit-linked | — | 9.3 | +13% |
| Capital light G/A | — | 9.0 | +7% |
| Traditional G/A | — | 1.9 | -7% |
| Employee benefits | — | 12.9 | +4% |
| Total | 34.5 | 37.5 | +9% |
| EUR billion | FY24 | FY25 | LFL Change |
|---|---|---|---|
| Individual | — | 10.5 | +6% |
| Group | — | 8.5 | +4% |
| Total | 17.5 | 19.0 | +5% |
| EUR billion | FY24 | FY25 |
|---|---|---|
| Protection flows | — | +4.9 |
| Health flows | — | +2.7 |
| Unit-linked flows | — | +1.5 |
| Capital light flows | — | +1.2 |
| Traditional G/A flows | — | -5.0 |
| Total | +1.5 | +5.4 |
Life & Health | Strong volume growth in Savings and Protection impacted by higher interest rates on discounting
| EUR billion unless otherwise mentioned | FY24 | FY25 | LFL Change |
|---|---|---|---|
| Protection & Health | — | 31.4 | -4% |
| Unit-linked | — | 8.5 | +18% |
| Capital-light G/A | — | 7.8 | -10% |
| Traditional G/A | — | 1.7 | -10% |
| Total | 50.9 | 49.4 | -2% |
| EUR billion | FY24 | FY25 | LFL Change |
|---|---|---|---|
| NB CSM (pre-tax) | 2.2 | 2.2 | +3% |
| EUR billion | FY24 | FY25 | LFL Change |
|---|---|---|---|
| NBV (post-tax) | 2.3 | 2.2 | stable |
- PVEP was impacted by higher interest rates on discounting despite strong growth in Life volumes p. 18.
- NB CSM was driven by robust Savings & Protection sales, with reported growth impacted by higher interest rates for discounting of future profits p. 18.
- NBV was broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France p. 18.
- NBV margin improved to 4.5% (prior: 4.4%) p. 18.
Life & Health | Growth in new business driving Normalized CSM growth
| EUR billion | CSM |
|---|---|
| FY24 | 33.6 |
| new business CSM | +2.2 |
| underlying return on in-force | +1.3 |
| CSM release | -3.0 |
| economic variance | +0.6 |
| operating variance | -0.3 |
| affiliates, FX & other | -1.4 |
| FY25 | 33.0 |
- Normalized CSM up by +2%, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates p. 19.
- Economic variance reflected government spreads tightening and positive equity market returns p. 19.
- Operating variance was driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland p. 19.
- FX impact was mainly driven by JPY and HKD depreciation p. 19.
- FY24 o/w Life EUR 25.8bn, Health EUR 7.7bn p. 19.
- FY25 o/w Life EUR 25.4bn, Health EUR 7.6bn p. 19.
- Normalized CSM growth was +2% p. 19.
Life & Health | Strong momentum in both short-term and long-term business
| EUR million | Underlying earnings |
|---|---|
| FY24 | 3,323 |
| short-term technical margin | +60 |
| long-term result incl. CSM release | +156 |
| financial result | -11 |
| tax, FX and others | -27 |
| FY25 | 3,501 |
- Short-term technical margin was strong, reflecting underwriting and claims initiatives that more than offset the impact of legislative change on the recoverability of value added tax in Mexico (EUR -0.1bn) p. 20.
- Long-term results were higher from an increase in CSM release (+8%) reflecting growth in reserve base, including from favorable equity market performance, and better margins p. 20.
- FY25 (+7% LFL) p. 20.
- FY24 earnings mix: short-term technical margin EUR 415m, long-term result incl. CSM release EUR 2,680m, financial result EUR 975m, tax & others -EUR 748m p. 20.
- FY25 earnings mix: short-term technical margin EUR 479m, long-term result incl. CSM release EUR 2,804m, financial result EUR 946m, tax & others -EUR 728m p. 20.
- Life underlying earnings: FY24 EUR 2.6bn → FY25 EUR 2.7bn (+4% LFL) p. 20.
- Health underlying earnings: FY24 EUR 0.7bn → FY25 EUR 0.8bn (+17% LFL) p. 20.
Growth in net income reflecting higher earnings & the gain from the sale of AXA IM
| EUR billion unless otherwise mentioned | FY24 | FY25 | Change (constant FX) |
|---|---|---|---|
| Property & Casualty | 5.5 | 5.9 | +9% |
| Life & Health | 3.3 | 3.5 | +7% |
| Asset Management | 0.4 | 0.2 | -57% |
| Holdings & other | -1.2 | -1.2 | — |
| Total underlying earnings | 8.1 | 8.4 | +6% |
| — | FY24 | FY25 | Change |
|---|---|---|---|
| Underlying EPS (reported basis) | 3.59 | 3.86 | +8% |
| from earnings growth | — | — | +6% |
| from capital management | — | — | +3% |
| from forex | — | — | -2% |
| from temporary earnings dilution from AXA IM sale | — | — | -1% |
- Non-financial flows: EUR +2.1bn in FY25 vs EUR -0.5bn in FY24, including EUR +2.2bn capital gains from AXA IM disposal p. 21.
- Financial flows: EUR -0.7bn in FY25 (including realized capital gains) vs EUR +0.3bn in FY24 p. 21.
- Net income: EUR 9.8bn in FY25 vs EUR 7.9bn in FY24 (+26% at constant FX) p. 21.
- Insurance business performance: Strong performance from insurance businesses p. 21.
- Holding costs: Stable holding cost, expected to remain at current level in 2026 p. 21.
- Net income drivers: Higher net income mainly reflecting higher underlying earnings and the gain from the sale of AXA IM; lower financial flows reflecting unfavorable forex impact p. 21.
- Includes
-1%from temporary earnings dilution from AXA IM sale due to the timing of anti-dilutive share buyback p. 21.
FY25 Financial Performance
| EUR billion unless otherwise mentioned | FY24 | HY25 | FY25 |
|---|---|---|---|
| Shareholders' equity (Group share) | 49.9 | 45.5 | 47.2 |
| SHE excl. OCI | 58.0 | 52.7 | 54.0 |
| Net OCI | -8.1 | -7.2 | -6.8 |
| SHE (excl. OCI & undated subordinated debt) | 53.2 | 47.0 | 49.4 |
| Debt gearing | 20.6% | 23.4% | 22.3% |
| Underlying ROE | 15.2% | 17.5% | 16.0% |
| EUR billion | Value |
|---|---|
| Opening SHE | 49.9 |
| Change in Net OCI | +1.3 |
| Net income | +9.8 |
| Dividend | -4.6 |
| Annual share buyback | -1.2 |
| Anti-dilutive share buyback | -3.5 |
| Undated subordinated debt | -0.3 |
| Forex | -3.5 |
| Other | -0.6 |
| Closing SHE | 47.2 |
| EUR billion | Value |
|---|---|
| Opening SHE | 45.5 |
| Change in Net OCI | +0.4 |
| Net income | +5.9 |
| Anti-dilutive share buyback | -3.5 |
| Undated subordinated debt | -1.2 |
| Forex | -0.1 |
| Other | +0.3 |
| Closing SHE | 47.2 |
Higher organic cash remittance and robust cash position at Holding
| EUR billion | FY24 | FY25 |
|---|---|---|
| Net cash remittance | 7.7 | 7.5 |
| Ordinary remittance | 7.1 | 7.5 |
| In-force treaties proceeds | 0.6 | — |
- In-force treaties proceeds in FY24 related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.
- Remittance ratio: 82% in FY25 (FY24: 82%)
| EUR billion | Value |
|---|---|
| FY24 Cash position | 4.0 |
| Net cash remittance | +7.5 |
| Dividend | -4.6 |
| Annual share buyback | -1.2 |
| Anti-dilutive share buyback | -3.5 |
| Holding costs | -1.3 |
| Change in net debt | +1.6 |
| M&A and other | +3.1 |
| FY25 Cash position | 5.6 |
- Holding costs include interest expenses.
- Anti-dilutive share buyback following the sale of AXA IM.
Solvency II at 224%
| EUR billion unless otherwise mentioned | EOF | SCR | Solvency II ratio (%) |
|---|---|---|---|
| FY24 | 55.9 | 25.9 | 216 |
| Regulatory & model changes | +0.2 | 0.0 | +0 |
| Normalized capital generation | +8.8 | +0.6 | +28 |
| Operating variance | -0.4 | 0.0 | -1 |
| Economic variance & FX | -2.1 | -1.2 | +4 |
| Dividend & buyback | -6.0 | 0.0 | -24 |
| Management actions | -0.1 | -0.2 | +2 |
| FY25 | 56.4 | 25.2 | 224 |
- Dividend & buyback comprises foreseeable dividends of EUR -4.8bn and provision for annual share buyback for 2026 of EUR -1.25bn.
- Management actions include debt & other.
| Sensitivity | Impact (pts) |
|---|---|
| Interest rate +50bps | +2 |
| Interest rate -50bps | -1 |
| Corporate spreads +50bps | -1 |
| Euro Sovereign spreads +50bps | -7 |
| Credit migration | -4 |
| Listed Equity +25% (excl. PE & Infra) | -1 |
| Listed Equity -25% (excl. PE & Infra) | +2 |
| PE & Infra +25% | +14 |
| PE & Infra -25% | -19 |
| Inflation swap curve +50bps | -5 |
- Euro Sovereign spreads +50bps assumes 50bps spread widening vs Euro swap curve.
- Credit migration assumes 20% of corporate bonds held are downgraded by one full letter / 3 notches.
Solvency II -impact of the end of grandfathering period and Solvency II revision
- Solvency II ratio as of December 31, 2025: 224% p. 25
- Grandfathering period end: Impact of -10pts to 215% on January 1, 2026 p. 25
- EUR 2.4bn grandfathered debt is no longer eligible as capital from January 1, 2026 p. 25
- Solvency II revision: Estimated impact of +17pts (to come into effect in 1Q27) p. 25
- No change expected in organic capital generation p. 25
- Additional capital flexibility p. 25
- Estimated based on SCR and EOF under Solvency II as of January 1, 2026, as if the revision had come into force on that date p. 25
Thomas Buberl, Group CEO conclusion
- Section divider featuring Thomas Buberl, Group CEO p. 26
Conclusion
- Record results at the top end of the target range while enhancing reserve prudence p. 27
- All businesses in excellent shape, delivering strong growth and profitability p. 27
- Diversified franchise well-positioned to capture future growth opportunities p. 27
- Laying foundations for the next plan and confident in delivering sustainable earnings growth p. 27
February 26, 2026 Q&A Full Year 2025 earnings
- Section divider for Q&A session on February 26, 2026 p. 28
AXA Investor Relations | Keep in touch
- Meet our management event calendar:
- March: Roadshows in Europe and US p. 29
- May 5: 1Q25 Activity Indicators in Paris p. 29
- June 2: BNP Paribas Exane CEO Conference in Paris p. 29
- June 2-4: Goldman Sachs European Financials Conference in Zurich p. 29
- July 31: HY26 Earnings Release in Paris p. 29
- September 21: AXA Investor Day in London p. 29
- Contact us details: Investor Relations phone +33 1 40 75 48 42; email investor.relations@axa.com p. 29
- Follow us website: www.axa.com p. 29
Appendices
- Section divider for appendices p. 30
| Topic | Page |
|---|---|
| Debt and Invested Assets | 31 |
| Additional P&C disclosures | 36 |
| Additional IFRS17 disclosures | 41 |
| Sustainability | 44 |
Gross financial debt and maturity breakdown as of December 31st, 2025
- (stacked bar) Gross financial debt:
- FY24: EUR 19.2bn total (Tier 1: EUR 4.8bn, Tier 2: EUR 10.8bn, Senior debt: EUR 3.5bn); debt gearing at 20.6% p. 32
- FY25: EUR 20.3bn total (Tier 1: EUR 4.6bn, Tier 2: EUR 12.2bn, Senior debt: EUR 3.5bn); debt gearing at 22.3% p. 32
- Jan 1st 2026 (End of the grandfathering period): EUR 20.3bn total (Tier 1: EUR 3.2bn, Tier 2: EUR 11.3bn, Senior debt: EUR 5.8bn, of which EUR 0.4bn redeemed in Jan 2026) p. 32
- (bar chart) Contractual maturity breakdown:
- 2028: EUR 0.5bn (Senior debt) p. 32
- 2030: EUR 0.9bn total (Tier 2: EUR 0.7bn, Senior debt: EUR 0.2bn) p. 32
- 2031-2039: EUR 1.5bn (Senior debt) p. 32
- ≥2040: EUR 11.3bn total (Tier 2: EUR 10.8bn, Senior debt: EUR 0.5bn) p. 32
- Undated: EUR 5.3bn total (Tier 1: EUR 4.6bn, Tier 2: EUR 0.7bn) p. 32
- Of which Grandfathered debt (Contractual): Tier 1 Undated: EUR 1.4bn; Tier 2 2030: EUR 0.7bn, ≥2040: EUR 0.2bn p. 32
- (bar chart) Economic maturity breakdown:
- 2026: EUR 0.1bn (Tier 1) p. 32
- 2027: EUR 2.4bn (Tier 2) p. 32
- 2028: EUR 0.6bn total (Tier 1: EUR 0.1bn, Senior debt: EUR 0.5bn) p. 32
- 2029: EUR 2.0bn (Tier 2) p. 32
- 2030: EUR 0.9bn total (Tier 2: EUR 0.7bn, Senior debt: EUR 0.2bn) p. 32
- 2031-2039: EUR 1.5bn total (Tier 1: EUR 0.4bn, Tier 2: EUR 1.1bn) p. 32
- ≥2040: EUR 0.5bn (Senior debt) p. 32
- Undated: EUR 4.7bn total (Tier 1: EUR 4.0bn, Tier 2: EUR 0.7bn) p. 32
- Of which Grandfathered debt (Economic): Tier 1: 2026: EUR 0.1bn, 2028: EUR 0.1bn, 2031-2039: EUR 0.4bn, Undated: EUR 0.8bn; Tier 2: 2030: EUR 0.7bn, ≥2040: EUR 0.2bn p. 32
- Redemption actions: In January 2026, AXA called the remaining T2 GF GBP 139m due 2054 callable 2034 5.625% issued January 2014, and the T1 GF EUR 250m perpetual callable 2010 floating issued January 2005 p. 32.
- Economic maturity definition: Takes into account the first date of step-up calls on institutionally placed subordinated debt; Solvency II RT1 debt has no step-up, so its undated nature is retained p. 32.
General Account invested assets
| EUR billion unless otherwise mentioned | Value | Share |
|---|---|---|
| Fixed income | 345 | 77% |
| Government bonds | 167 | 37% |
| Corporate bonds and loans | 121 | 27% |
| Other fixed income | 56 | 13% |
| Real estate | 41 | 9% |
| Infrastructure equity | 10 | 2% |
| Listed equities | 10 | 2% |
| Private equity and hedge funds | 23 | 5% |
| Cash | 19 | 4% |
| Policy loans | 2 | 0% |
| Total Insurance Invested Assets | 450 | 100% |
- Total General Account invested assets: EUR 450bn total, with a duration gap at -0.4 year
- Other fixed income includes Asset Backed Securities (EUR 25bn), Residential Loans (EUR 16bn), Commercial & Agricultural Loans (EUR 7bn), and Agency Pools (EUR 8bn)
- Listed equities includes hedges (listed equities excluding hedges at EUR 14bn)
- Private equity and hedge funds includes Private Equity (EUR 17bn), Hedge Funds (EUR 5bn), and Non-listed Equities (EUR 1bn)
Structured and Private Credit assets
| EUR billion unless otherwise mentioned | Value | % of total G/A portfolio |
|---|---|---|
| Residential Mortgages | 16 | 4% |
| CLO & ABS | 25 | 6% |
| Infrastructure debt | 8 | 2% |
| CRE debt | 8 | 2% |
| Mid-Market lending | 10 | 2% |
| Other | 2 | 0% |
| Total Structured and Private Credit Assets | 69 | 15% |
- Residential Mortgages: EUR 6bn Dutch mortgages, NHG guaranteed; EUR 10bn self-originated mortgages in Switzerland (56% LTV) and Germany (45% LTV)
- CLO & ABS: 91% senior CLOs with circa 40% subordination (100% rated AAA-A and 92% rated AAA-AA)
- Infrastructure debt: skewed towards resilient industries (Telecom, Utilities, Transport)
- CRE debt: strong sector diversification (mainly logistics, residential and retail), mostly in Europe, and circa 60% LTV
- Mid-Market lending: strong diversification with EUR 8m average ticket; investments through SMAs with strict underwriting guidelines: senior secured, covenants, restrictions on asset sales and sector allocation
- Total Structured and Private Credit Assets: 54% participating
Investment portfolio | Fixed Income reinvestment
| EUR billion unless otherwise mentioned | Share | Yield |
|---|---|---|
| Investment grade credit | 40% | — |
| Government bonds & related | 32% | — |
| ABS/CLO/IG fund financing | 21% | — |
| Below investment grade credit | 7% | — |
| Public fixed income | — | 3.5% |
| Private & Structured fixed income | — | 4.7% |
| Total fixed income | — | 3.9% |
- Reinvestment highlights:
- EUR 57bn fixed income invested at 3.9% p. 35
- Average duration of 9 years p. 35
- Includes EUR 19.7bn of Private & Structured Credit invested at 4.7% (CLOs, ABS, Infra & CRE debt, Fund financing and Private HY) p. 35
- Gradual shift from alternative total return assets to Private & Structured credit p. 35
- Additional P&C disclosures is covered on page 36 p. 36.
- Other sections in the appendix include Debt and Invested Assets on page 31, Additional IFRS17 disclosures on page 41, and Sustainability on page 44 p. 36.
AXA XL Insurance | Large Commercial & Specialty business
| USD billion unless otherwise mentioned | GWP by line | GWP by geography |
|---|---|---|
| Casualty | 35% | — |
| Property | 29% | — |
| Specialty | 19% | — |
| Professional lines (including Cyber) | 17% | — |
| Americas | — | 46% |
| Europe & APAC | — | 35% |
| UK & Lloyds | — | 19% |
- Market position: Top 3 globally in Multinational Programs, Marine, and Fine Art & Specie p. 37.
- (bubble chart) Cycle management: Property has the highest profitability and highest ex-price growth; Specialty has medium profitability and medium ex-price growth; Casualty has medium-low profitability and medium-low ex-price growth; Professional lines has the lowest profitability and lowest ex-price growth p. 37.
P&C | Focus on Reserves
| % | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Claims reserves ratio (IFRS4) | 179% | 185% | 193% | 188% | 189% | — | — | — |
| Claims reserves ratio (IFRS17) | — | — | — | — | 198% | 195% | 180% | 175% |
| Technical reserves ratio (IFRS4) | 213% | 227% | 233% | 226% | 227% | — | — | — |
| Technical reserves ratio (IFRS17) | — | — | — | — | 234% | 232% | 216% | 210% |
P&C | 2026 Simplified Group Nat Cat Reinsurance Program 1
| EUR billion | Capacity | Retention |
|---|---|---|
| EU Windstorm | 4.0 | 600m |
| Europe Flood | 2.1 | 450m |
| Europe Earthquake | 2.1 | 400m |
| NA Hurricane | 1.2 | 600m |
| NA Earthquake | 1.2 | 600m |
| Other perils | — | 400m |
- Retention levels: Stable retention levels maintained in 2026 as in 2025.
- NA Hurricane: varying retention between MX at EUR 400m and NA at EUR 600m.
- NA Earthquake: varying retention between MX at EUR 400m and NA at EUR 600m.
- Other perils: includes Turkey earthquake, other Europe and NA perils, South America Earthquake, and other secondary perils.
- Reinsurance segment: Alternative Capital & Cat Bonds utilized.
P&C | AXA Group earnings deviation with different levels of Nat Cat cost 1 in 2026
- Nat Cat definition: Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance p. 40.
- Deviation baseline: Compared to a normalized level of costs expected in an average year, which is ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance p. 40.
- (bar) Earnings deviation: Group underlying earnings deviation to average Nat Cat charges in 2026 net of reinsurance, post-tax p. 40.
- More severe years: Negative deviation in ca. 40% of cases; 1/20y (95th percentile) EUR -1.2bn, 1/10y (90th percentile) EUR -0.8bn, 1/5y (80th percentile) EUR -0.4bn p. 40.
- Median: 50th percentile at EUR +0.1bn p. 40.
- Less severe years: Positive deviation in ca. 60% of cases; 1/5y (20th percentile) EUR +0.5bn, 1/10y (10th percentile) EUR +0.7bn, 1/20y (5th percentile) EUR +0.8bn p. 40.
- (bar) Expected Nat Cat: Average expected Nat Cat charges net of reinsurance, pre-tax p. 40.
- FY25: EUR 2.6bn (Estimated impact on GEP: ca. 4.5%) p. 40.
- FY26: EUR 2.7bn (Estimated impact on GEP: ca. 4.5%) p. 40.
- Table of contents p. 41:
- 1. Debt and Invested Assets p. 31
- 2. Additional P&C disclosures p. 36
- 3. Additional IFRS17 disclosures p. 41
- 4. Sustainability p. 44
P&C | Margin analysis
| EUR million unless otherwise mentioned | FY25 | Change vs FY24 | Other metrics |
|---|---|---|---|
| Current Accident Year Undiscounted Technical Margin | 2,778 | +707 | — |
| Gross Earned Premiums | 57,656 | +6% | — |
| Current Accident Year Undiscounted Combined Ratio | 95.2% | -1.0pt | — |
| Nat Cats | 3.4% | -0.4pt | — |
| Current Accident Year Discounting | 2,009 | +115 | — |
| Discounting Ratio (in Combined Ratio points) | -3.5% | +0.0pt | — |
| Current Accident Year Net Claims reserves | 19.0bn | — | — |
| Duration | 4.0 years | — | — |
| Current Accident Year Discount rate | 2.8% | — | — |
| Prior Years' Reserve Development (PYD) | 622 | -341 | — |
| PYD ratio | -1.1% | +0.7pt | — |
| Investment Income | 3,988 | +435 | — |
| FY25 Average Assets | 115bn | — | — |
| Asset book yield | 3.5% | — | — |
| FY25 Reinvestment yield (on fixed income assets) | 4.3% | — | — |
| Insurance Finance Expenses | -1,358 | -235 | — |
| FY24 Reserves at locked-in rate | 71bn | — | — |
| Liability book yield | 1.9% | — | — |
| Underlying Earnings before tax | 8,040 | +681 | — |
| Tax | -2,060 | -169 | — |
| Affiliates, Minority interests & Other | -108 | -10 | — |
| Underlying Earnings | 5,872 | +501 | growth vs. FY24 at constant FX of +9% |
| Change in discount rate | Impact (EUR billion) |
|---|---|
| +25bps | +0.2 |
| -25bps | -0.2 |
| Item | Value |
|---|---|
| 2026e Insurance Finance Expenses (pre-tax) | ~ -1.4bn |
| Sensitivity to 2025 current AY Discount +25bps | ~ -50m |
| Sensitivity to 2025 current AY Discount -25bps | ~ +50m |
L&H | Margin analysis
| EUR million unless otherwise mentioned | FY25 | Change vs FY24 | Other metrics |
|---|---|---|---|
| Short-term Technical Margin | 479 | +60 | — |
| Gross Earned Premiums | 17,416 | +10% | — |
| All Year Combined Ratio | 97.2% | -0.1pt | includes recapture of Laya |
| Long-term Technical Margin | 2,804 | +156 | — |
| CSM release | 2,954 | +215 | — |
| Technical experience | -150 | -58 | — |
| Investment Income (non-VFA only) | 2,484 | -1 | — |
| FY25 Average Assets | 98bn | — | — |
| Asset book yield | 2.5% | — | — |
| FY25 Reinvestment yield (on fixed income assets) | 3.8% | — | — |
| Insurance Finance Expenses (non-VFA only) | -1,538 | -9 | — |
| FY24 Reserves at locked-in rate | 62bn | — | — |
| Liability book yield | 2.5% | — | — |
| Underlying Earnings before tax | 4,229 | +205 | — |
| Tax | -800 | +65 | — |
| Affiliates, Minority interests & Other | 72 | -51 | — |
| Underlying Earnings | 3,501 | +219 | growth vs. FY24 at constant FX of +7% |
| Scenario | EUR billion |
|---|---|
| Baseline | 33.3 |
| Interest rates +50bps | -0.8 |
| Interest rates -50bps | +0.6 |
| Sovereign spreads +50bps | -1.9 |
| Sovereign spreads -50bps | +1.9 |
| Corporate spread +50bps | -0.8 |
| Corporate spread -50bps | +0.7 |
| Equities +25% | +1.8 |
| Equities -25% | -2.2 |
- Table of contents p. 44:
- 1. Debt and Invested Assets p. 31
- 2. Additional P&C disclosures p. 36
- 3. Additional IFRS17 disclosures p. 41
- 4. Sustainability p. 44
Expanding AXA's role in society: AXA for Progress Index 1
| Category | Target | 2025 Result |
|---|---|---|
| Climate transition financing | EUR 5bn per year | EUR 6.4bn |
| Community resilience financing | >EUR 500m per year | EUR 1.4bn |
| P&C GWP to support transition underwriting (cumulative 2024-2026) | EUR 6bn | EUR 4.6bn |
| Climate adaptation solutions & services (cumulative 2024-2026) | >20,000 | 19,698 cumulative 2024-2025 |
| Inclusive insurance customers | >20m by 2026 | 20.6m |
| AXA Group employees trained on climate adaptation | >80,000 by 2026 | 46,420 |
| Absolute carbon emissions reduction | -50% by 2030 | -64% reduction against 2019 |
| Employee volunteering engagement | 50% of AXA Group employees engaged in volunteering activities by 2026 | 56% |
- Climate adaptation solutions & services target (cumulative 2024-2026): >20,000 (target revised in 2025 from >9,000); 2025 Result: 19,698 cumulative 2024-2025 p. 45
- Absolute carbon emissions reduction target: -50% by 2030 (against 2019 baseline; scope: energy Scopes 1 and 2, car fleet and business travel) and offset of residual emissions; 2025 Result: -64% reduction against 2019 p. 45
Sustainability Performance & Ratings
| Provider | 2025 Score / Rating |
|---|---|
| S&P Global | 97th percentile¹ in Dow Jones Best-in-Class Europe & World indices |
| MSCI | AAA |
| CDP | B |
| Morningstar Sustainalytics | 17.0 - Low risk |
| FTSE Russell | 4.3/5 in FTSE4Good Index Series |
- "The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (more precisely AXA Restricted Shares). Results as of February 6th, 2026."
Scope
- France: includes insurance activities, banking activities and holding p. 47
- Europe: includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holdings), Italy (insurance activities), Prima (insurance activities) and AXA Life Europe (insurance activities) p. 47
- AXA XL: includes insurance and reinsurance activities and holding p. 47
- Asia, Africa & EME-LATAM: includes: p. 47
- Asia: Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, China P&C, South Korea, and Asia Holdings which are fully consolidated, and China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S and India (Life activities disposed on March 11, 2024 and holding) businesses which are consolidated under the equity method and contribute only to NBV, PVEP, the underlying earnings and net income p. 47
- Africa: Morocco (insurance activities and holding) and Nigeria (insurance activities and holding), Egypt (insurance activities and holding) which are fully consolidated p. 47
- EME-LATAM: Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding) and Türkiye (insurance activities and holding) which are fully consolidated as well as Russia (Reso) (insurance activities) which consolidated under the equity method and contributes only to the net income p. 47
- AXA Mediterranean Holdings p. 47
- Transversal & Other: includes AXA Assistance, AXA Liabilities Managers, AXA and other Central Holdings p. 47
- AXA Investment Managers (until July 1, 2025): includes AXA Investment Managers, Select (previously referred to as Architas) and Capza which are fully consolidated and Asian joint ventures which are consolidated under the equity method p. 47
- Accounting standards: Unless otherwise specified herein, all comparative figures going back to 2023 are under the IFRS17/9 accounting standards that became effective on January 1, 2023; figures for financial periods prior to 2023 have not been restated under IFRS17/9 and are presented under IFRS4 p. 47
Glossary
- Capital-light G/A products: encompass all products with no guarantees, with guarantees at maturity only or with guarantees equal to or lower than 0% p. 48
- Contractual Service Margin (CSM): a component of the carrying amount of asset or liability for a group of insurance contracts representing the unearned profit to be recognized as services are provided to policyholders p. 48
- CSM release: a portion of CSM stock net of reinsurance at the end of the defined period flowing through profit and loss representing the estimated profit earned by the insurer for providing insurance services during the reporting period p. 48
- Economic variance: corresponds to the variance of the year-end CSM arising from changes in market conditions, net of the underlying return on in-force p. 48
- Financial result: consists of investment income on assets backing BBA and PAA contracts as well as assets backing shareholder's equity, net of the insurance finance expenses (IFE) defined as the unwind of the present value of future cash flow p. 48
- Gross Written Premiums and Other Revenues (GWP & Other Revenues): represent the insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business); Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities) p. 48
- New Business Value (NBV): the value of newly issued contracts during the current year, consisting of the sum of (i) the new business contractual service margin, (ii) the present value of the future profits of short-term newly issued contracts during the period, carried by Life entities, considering expected renewals, (iii) the present value of the future profits of pure investment contracts accounted for under IFRS 9, net of (iv) the cost of reinsurance, (v) taxes and (vi) minority interests p. 48
- New Business CSM (NB CSM): a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided p. 48
- New Business Value margin (NBV margin): ratio of (i) NBV, representing the value of newly issued contracts during the current year, to (ii) PVEP p. 48
- Operating variance: the variation of the year-end CSM versus the expected at opening due to (i) the differences between realized and expected operational assumptions, (ii) changes in assumptions such as mortality, longevity, lapses and expenses, and (iii) impact of model changes; operating variance is net of reinsurance p. 48
- Present value of expected premiums (PVEP): the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term; PVEP is discounted at the reference interest rate and PVEP is Group share p. 48
- Technical experience: consists of the impacts on the underlying earnings of (i) the difference between the expected and incurred cash-flows of the defined period, (ii) the risk adjustment release, (iii) the changes in onerous contracts, and (iv) the other long-term elements which are mainly composed of non-attributable expenses p. 48
- Underlying return on in-force: represents the release of Time Value of Options & Guarantees (TVOG) plus the unwind of CSM at the reference rate plus the underlying financial over-performance p. 48
February 26, 2026 Thank you Full Year 2025 earnings
- Presentation conclusion: Full Year 2025 Earnings presentation concluded on February 26, 2026 p. 49
Abbreviations
- AA: Senior bond rating (Standard & Poor's)
- AAA: Senior bond rating (Standard & Poor's)
- ABS: Asset-Backed Securities
- AEP: Aggregate Exceedance Probability
- AI: Artificial Intelligence
- APAC: Asia-Pacific
- AXA IM: AXA Investment Managers
- AXA XL: AXA XL (AXA's large property and casualty commercial lines and specialty risk division)
- AY: Accident Year
- BBA: Beneficial interest in a Block of business of Annuities
- CDP: Carbon Disclosure Project
- CLO: Collateralized Loan Obligation
- CRE: Commercial Real Estate
- CSA: Corporate Sustainability Assessment
- CSM: Contractual Service Margin
- CY: Calendar Year
- DPS: Dividend Per Share
- EME: Emerging Markets
- EOF: Eligible Own Funds
- EPS: Earnings Per Share
- ESG: Environmental, Social, and Governance
- EU: European Union
- EUR: Euro
- FX: Foreign Exchange
- GAAP: Generally Accepted Accounting Principles
- GEP: Gross Earned Premiums
- GF EUR: Grandfathered Euro
- GF GBP: Grandfathered Great British Pound
- GWP: Gross Written Premiums
- HKD: Hong Kong Dollar
- HY: High Yield
- IFE: Insurance Finance Expenses
- IFRS: International Financial Reporting Standards
- IG: Investment Grade
- JPY: Japanese Yen
- LATAM: Latin America
- LFL: Like-for-Like
- LTV: Loan-to-Value
- MSCI: Morgan Stanley Capital International
- MX: Mexico
- NA: North America
- NB CSM: New Business Contractual Service Margin
- NBV: New Business Value
- NHG: Nationale Hypotheek Garantie (National Mortgage Guarantee)
- NPS: Net Promoter Score
- OCI: Other Comprehensive Income
- PAA: Premium Allocation Approach
- PE: Private Equity
- PVEP: Present Value of Expected Profits
- PYD: Prior Years' Reserve Development
- ROE: Return On Equity
- SCR: Solvency Capital Requirement
- SHE: Shareholders' Equity
- SME: Small and Medium-sized Enterprises
- TVOG: Time Value of Options & Guarantees
- UEPS: Underlying Earnings Per Share
- UK: United Kingdom
- US: United States
- USD: United States Dollar
- VAT: Value Added Tax
- VFA: Variable Fee Approach